| | |
Page
|
| |||
| | | | 1 | | | |
TRADEMARKS | | | | | 1 | | |
| | | | 1 | | | |
| | | | 1 | | | |
| | | | 7 | | | |
| | | | 9 | | | |
SUMMARY | | | | | 22 | | |
| | | | 37 | | | |
| | | | 38 | | | |
| | | | 39 | | | |
| | | | 43 | | | |
| | | | 44 | | | |
| | | | 101 | | | |
| | | | 102 | | | |
| | | | 137 | | | |
| | | | 144 | | | |
| | | | 146 | | | |
| | | | 151 | | | |
| | | | 153 | | | |
| | | | 162 | | | |
| | | | 164 | | | |
| | | | 165 | | | |
| | | | 170 | | | |
| | | | 171 | | | |
| | | | 182 | | | |
| | | | 197 | | | |
| | | | 206 | | | |
| | | | 244 | | | |
| | | | 247 | | | |
| | | | 260 | | | |
| | | | 268 | | | |
| | | | 276 | | | |
| | | | 279 | | | |
| | | | 285 | | | |
| | | | 294 | | | |
| | | | 294 | | | |
| | | | 295 | | |
| | |
Page
|
| |||
| | | | 295 | | | |
| | | | 295 | | | |
EXPERTS | | | | | 295 | | |
| | | | 296 | | | |
| | | | F-1 | | | |
| | | | A-1 | | | |
| | | | B-1 | | | |
| | | | C-1 | | | |
| | | | D-1 | | | |
| | | | E-1 | | | |
| | | | F-1 | | | |
| | | | G-1 | | | |
| | | | H-1 | | | |
| | | | I-1 | | | |
| | | | J-1 | | | |
| | | | K-1 | | |
| | |
Assuming
No Redemptions of Public Shares |
| |
Percentage
|
| |
Assuming
Maximum Redemptions of Public Shares(1) |
| |
Percentage
|
| ||||||||||||
Hyperfine Stockholders
|
| | | | 37,840,567 | | | | | | 43.4% | | | | | | 37,840,567 | | | | | | 56.9% | | |
Liminal Stockholders
|
| | | | 10,280,885 | | | | | | 11.8% | | | | | | 10,280,885 | | | | | | 15.4% | | |
Public Shareholders
|
| | | | 20,700,000 | | | | | | 23.7% | | | | | | 0 | | | | | | 0% | | |
PIPE Investors
|
| | | | 12,610,000 | | | | | | 14.5% | | | | | | 12,610,000 | | | | | | 19.0% | | |
Sponsor
|
| | | | 5,684,000 | | | | | | 6.5% | | | | | | 5,684,000 | | | | | | 8.5% | | |
Other Initial Shareholders
|
| | | | 105,000 | | | | | | 0.1% | | | | | | 105,000 | | | | | | 0.2% | | |
| | | | | 87,220,452 | | | | | | 100% | | | | | | 66,520,452 | | | | | | 100% | | |
| | |
Assuming No
Redemptions of Public Shares |
| |
Assuming
Maximum Redemptions of Public Shares |
| ||||||
Entities controlled by Jonathan M. Rothberg, Ph.D.
|
| | | | 80.9% | | | | | | 85.7% | | |
Other Hyperfine Stockholders
|
| | | | 7.7% | | | | | | 8.1% | | |
Other Liminal Stockholders
|
| | | | 0.9% | | | | | | 0.9% | | |
Public Shareholders
|
| | | | 5.6% | | | | | | 0.0% | | |
PIPE Investors
|
| | | | 3.4% | | | | | | 3.6% | | |
Sponsor
|
| | | | 1.5% | | | | | | 1.6% | | |
Other Initial Shareholders
|
| | | | <0.1% | | | | | | <0.1% | | |
Total
|
| | | | 100% | | | | | | 100% | | |
| SOURCES | | | | | | | |
|
Hyperfine Equity Rollover (1)
|
| | | $ | 452.1 | | |
|
Liminal Equity Rollover (2)
|
| | | $ | 104.5 | | |
|
Proceeds from Trust Account
|
| | | $ | 207.0 | | |
|
PIPE Investors
|
| | | $ | 126.1 | | |
|
Hyperfine Cash
|
| | | $ | 57.7 | | |
|
Liminal Cash
|
| | | $ | 0.2 | | |
|
Sponsor Founder Shares
|
| | | $ | 57.9 | | |
|
Total Sources
|
| | | $ | 1,005.5 | | |
| USES | | | | | | | |
|
Equity Consideration to Existing Hyperfine Investors
|
| | | $ | 452.1 | | |
|
Equity Consideration to Existing Liminal Investors
|
| | | $ | 104.5 | | |
|
Cash to Balance Sheet
|
| | | $ | 365.6 | | |
|
Repayment of Paycheck Protection Program ("PPP") Loan
|
| | | $ | 0.2 | | |
|
Estimated Transaction Expenses (3)
|
| | | $ | 25.2 | | |
|
Sponsor Founder Shares
|
| | | $ | 57.9 | | |
|
Total Uses
|
| | | $ | 1,005.5 | | |
| SOURCES | | | | | | | |
|
Hyperfine Equity Rollover (1)
|
| | | $ | 452.1 | | |
|
Liminal Equity Rollover (2)
|
| | | $ | 104.5 | | |
|
Proceeds from Trust Account
|
| | | $ | 0.0 | | |
|
PIPE Investment
|
| | | $ | 126.1 | | |
|
Hyperfine Cash
|
| | | $ | 57.7 | | |
|
Liminal Cash
|
| | | $ | 0.2 | | |
|
Sponsor Founder Shares
|
| | | $ | 57.9 | | |
|
Total Sources
|
| | | $ | 798.5 | | |
| USES | | | | | | | |
|
Equity Consideration to Existing Hyperfine Investors
|
| | | $ | 452.1 | | |
|
Equity Consideration to Existing Liminal Investors
|
| | | $ | 104.5 | | |
|
Cash to Balance Sheet
|
| | | $ | 158.6 | | |
|
Repayment of PPP Loan
|
| | | $ | 0.2 | | |
|
Estimated Transaction Expenses (3)
|
| | | $ | 25.2 | | |
|
Sponsor Founder Shares
|
| | | $ | 57.9 | | |
|
Total Uses
|
| | | $ | 798.5 | | |
|
| | |
For the Nine
Months Ended September 30, 2021 (unaudited) |
| |
For the Period from
November 18, 2020 (inception) through December 31, 2020 (audited) |
| ||||||
Statement of Operations Data: | | | | | | | | | | | | | |
Operating and formation costs
|
| | | $ | 2,494,910 | | | | | $ | 5,000 | | |
Loss from operations
|
| | | $ | (2,494,910) | | | | | $ | (5,000) | | |
Balance Sheet Data (at period end): | | | | | | | | | | | | | |
Total assets
|
| | | $ | 207,942,096 | | | | | $ | 304,412 | | |
Total liabilities
|
| | | $ | 9,191,417 | | | | | $ | 284,412 | | |
Shareholders’ (deficit) equity: | | | | | | | | | | | | | |
Preference shares, $0.0001 par value; 5,000,000 shares authorized; no
shares issued and outstanding |
| | | | — | | | | | | — | | |
Class A ordinary shares, $0.0001 par value; 500,000,000 shares
authorized; 614,000 and no shares issued and outstanding as of September 30, 2021 and December 31, 2020, (excluding 20,700,000 shares subject to possible redemption at September 30, 2021 and no shares at December 31, 2020) respectively |
| | | $ | 61 | | | | | | — | | |
Class B ordinary shares, $0.0001 par value; 50,000,000 shares authorized; 5,175,000 shares issued and outstanding at September 30. 2021 and December 30, 2020
|
| | | | 518 | | | | | | 518 | | |
Additional paid-in capital
|
| | | | — | | | | | | 24,482 | | |
Accumulated deficit
|
| | | | (8,249,900) | | | | | | (5,000) | | |
Total shareholders’ (deficit) equity
|
| | | $ | (8,249,321) | | | | | $ | 20,000 | | |
| | |
For the Nine
Months Ended September 30, 2021 (unaudited) |
| |
For the Period from
November 18, 2020 (inception) through December 31, 2020 (audited) |
| ||||||
Cash Flow Data: | | | | | | | | | | | | | |
Net cash used in operating activities
|
| | | $ | (958,203) | | | | | | — | | |
Net cash used in investing activities
|
| | | $ | (207,000,000) | | | | | | — | | |
Net cash provided by financing activities
|
| | | $ | 208,483,607 | | | | | | — | | |
| | |
Nine Months Ended September 30,
|
| |
Year Ended December 31,
|
| ||||||||||||||||||
(in thousands)
|
| |
2021
|
| |
2020
|
| |
2020
|
| |
2019
|
| ||||||||||||
Sales
|
| | | $ | 1,060 | | | | | $ | 87 | | | | | $ | 294 | | | | | $ | — | | |
Cost of sales
|
| | | | 1,774 | | | | | | 368 | | | | | | 771 | | | | | | — | | |
Total operating expenses
|
| | | | 38,067 | | | | | | 16,350 | | | | | | 23,014 | | | | | | 19,968 | | |
Loss from operations
|
| | | | (38,781) | | | | | | (16,631) | | | | | | (23,491) | | | | | | (19,968) | | |
Loss before income taxes
|
| | | | (38,766) | | | | | | (16,565) | | | | | | (23,427) | | | | | | (19,415) | | |
Provision for income taxes
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Net loss and comprehensive loss
|
| | | | (38,766) | | | | | | (16,565) | | | | | | (23,427) | | | | | | (19,415) | | |
| | |
As of
September 30, 2021 |
| |
As of December 31,
|
| ||||||||||||
(in thousands)
|
| |
2020
|
| |
2019
|
| ||||||||||||
Cash and cash equivalents
|
| | | $ | 65,475 | | | | | $ | 62,676 | | | | | $ | 26,441 | | |
Restricted cash
|
| | | | 3,467 | | | | | | 1,610 | | | | | | — | | |
Total assets
|
| | | | 81,368 | | | | | | 71,526 | | | | | | 30,571 | | |
Total liabilities
|
| | | | 14,332 | | | | | | 4,294 | | | | | | 1,789 | | |
Convertible preferred stock
|
| | | | 168,097 | | | | | | 128,286 | | | | | | 68,646 | | |
Total stockholders’ deficit
|
| | | | (101,061) | | | | | | (61,054) | | | | | | (39,864) | | |
| | |
Historical
|
| |
Pro Forma
|
| ||||||||||||||||||
| | |
HealthCor
|
| |
Hyperfine
and Liminal |
| |
No
redemption scenario |
| |
Maximum
redemption scenario |
| ||||||||||||
Statement of Operations Data – For the Nine Months Ended September 30, 2021
|
| | | | | | | | | | | | | | | | | | | | | | | | |
Sales
|
| | | $ | — | | | | | $ | 1,060 | | | | | $ | 1,060 | | | | | $ | 1,060 | | |
Cost of sales
|
| | | | — | | | | | | 1,774 | | | | | | 1,774 | | | | | | 1,774 | | |
Total Operating Expenses
|
| | | | 2,494 | | | | | | 38,067 | | | | | | 42,776 | | | | | | 42,776 | | |
Loss from operations
|
| | | | (2,494) | | | | | | (38,781) | | | | | | (43,490) | | | | | | (43,490) | | |
Net loss and comprehensive loss
|
| | | | (2,480) | | | | | | (38,766) | | | | | | (43,475) | | | | | | (43,475) | | |
Basic and diluted net loss per share, Class A Ordinary shares subject to possible redemption
|
| | | | (0.10) | | | | | | n/a | | | | | | n/a | | | | | | n/a | | |
Basic and diluted net loss per share(1)
|
| | | | (0.10) | | | | | | (7.41) | | | | | | (0.50) | | | | | | (0.65) | | |
Basic and diluted net loss per share, Class B Ordinary shares not subject to possible redemption
|
| | | | (0.10) | | | | | | n/a | | | | | | n/a | | | | | | n/a | | |
| | |
Historical
|
| |
Pro Forma
|
| ||||||||||||||||||
|
HealthCor
|
| |
Hyperfine and
Liminal |
| |
No redemption
scenario |
| |
Maximum redemption
scenario |
| ||||||||||||||
Statement of Operations Data – For the Year Ended December 31, 2020
|
| | | | | | | | | | | | | | | | | | | | | | | | |
Sales
|
| | | $ | — | | | | | $ | 294 | | | | | $ | 294 | | | | | $ | 294 | | |
Cost of sales
|
| | | | — | | | | | | 771 | | | | | | 771 | | | | | | 771 | | |
Total Operating Expenses
|
| | | | 5 | | | | | | 23,014 | | | | | | 30,177 | | | | | | 30,177 | | |
Loss from operations
|
| | | | (5) | | | | | | (23,491) | | | | | | (30,654) | | | | | | (30,654) | | |
Net loss and comprehensive loss
|
| | | | (5) | | | | | | (23,427) | | | | | | (30,590) | | | | | | (30,590) | | |
Basic and diluted net loss per share(1)
|
| | | | (0.00) | | | | | | (5.04) | | | | | | (0.35) | | | | | | (0.46) | | |
| | |
Historical
|
| |
Pro Forma
|
| ||||||||||||||||||
|
HealthCor
|
| |
Hyperfine and
Liminal |
| |
No redemption
scenario |
| |
Maximum redemption
scenario |
| ||||||||||||||
Balance Sheet Data – As of September 30, 2021
|
| | | | | | | | | | | | | | | | | | | | | | | | |
Total current assets
|
| | | $ | 928 | | | | | $ | 76,306 | | | | | $ | 385,477 | | | | | $ | 178,477 | | |
Total assets
|
| | | | 207,942 | | | | | | 81,368 | | | | | | 390,539 | | | | | | 183,539 | | |
Total current liabilities
|
| | | | 1,946 | | | | | | 13,814 | | | | | | 13,637 | | | | | | 13,637 | | |
Total liabilities
|
| | | | 9,191 | | | | | | 14,332 | | | | | | 13,977 | | | | | | 13,977 | | |
Common stock subject to possible redemption
|
| | | | 207,000 | | | | | | — | | | | | | — | | | | | | — | | |
Convertible preferred stock
|
| | | | — | | | | | | 168,097 | | | | | | — | | | | | | — | | |
Total stockholders’ equity (deficit)
|
| | | | (8,249) | | | | | | (101,061) | | | | | | 376,562 | | | | | | 169,562 | | |
| | |
Historical
|
| |
Pro forma
|
| ||||||||||||||||||
| | |
HealthCor
|
| |
Hyperfine
and Liminal |
| |
No
redemption scenario |
| |
Maximum
redemption scenario |
| ||||||||||||
As of and for the nine months ended September 30, 2021 | | | | | | | | | | | | | | | | | | | | | | | | | |
Book value per share – basic and diluted(1)
|
| | | $ | (1.42) | | | | | $ | (15.54) | | | | | $ | 4.32 | | | | | $ | 2.55 | | |
Net loss per share, Class A Ordinary shares subject to possible
redemption – basic and diluted |
| | | $ | (0.10) | | | | | | n/a | | | | | | n/a | | | | | | n/a | | |
Net loss per share – basic and diluted(2)
|
| | | $ | (0.10) | | | | | $ | (7.41) | | | | | $ | (0.50) | | | | | $ | (0.65) | | |
Net loss per share, Class B Ordinary shares not subject to possible redemption – basic and diluted
|
| | | $ | (0.10) | | | | | | n/a | | | | | | n/a | | | | | | n/a | | |
For the year ended December 31, 2020
|
| | | | | | | | | | | | | | | | | | | | | | | | |
Net loss per share – basic and diluted(2)
|
| | | $ | (0.00) | | | | | $ | (5.04) | | | | | $ | (0.35) | | | | | $ | (0.46) | | |
Selected Company
|
| |
Enterprise Value
($mm) |
| |
Enterprise
Value/2023E Revenue |
| |
Revenue
CAGR 2021 – 2023E |
| |||||||||
Butterfly Network, Inc.
|
| | | $ | 1,505 | | | | | | 6.4x | | | | | | 73.7% | | |
Inari Medical, Inc.
|
| | | $ | 3,782 | | | | | | 9.8x | | | | | | 24.9% | | |
Inspire Medical Systems, Inc.
|
| | | $ | 4,495 | | | | | | 13.0x | | | | | | 33.3% | | |
Pulmonx Corporation
|
| | | $ | 1,046 | | | | | | 11.0x | | | | | | 38.8% | | |
Shockwave Medical, Inc.
|
| | | $ | 5,050 | | | | | | 12.1x | | | | | | 43.7% | | |
Silk Road Medical, Inc.
|
| | | $ | 1,541 | | | | | | 8.5x | | | | | | 30.6% | | |
Median | | | | | — | | | | | | 10.4x | | | | | | 38.0% | | |
Hyperfine, Inc. and Liminal Sciences, Inc.
|
| | | $ | 580 | | | | | | 10.7x | | | | | | 384.4% | | |
| | |
2021
|
| |
2022
|
| |
2023
|
| |
2024
|
| |
2025
|
| |||||||||||||||
Revenue ($ in millions)
|
| | | $ | 2.3 | | | | | $ | 16.3 | | | | | $ | 54.2 | | | | | $ | 141.1 | | | | | $ | 301.6 | | |
% Year on year revenue growth
|
| | | | NM | | | | | | 607% | | | | | | 232% | | | | | | 160% | | | | | | 114% | | |
Operating Expenses ($ in millions)
|
| | | $ | 68.8 | | | | | $ | 128.9 | | | | | $ | 168.4 | | | | | $ | 200.8 | | | | | $ | 228.6 | | |
% Gross Margin
|
| | | | NM | | | | | | 48% | | | | | | 66% | | | | | | 71% | | | | | | 72% | | |
| | |
Delaware
|
| |
Cayman Islands
|
|
Stockholder/Shareholder Approval of Business Combinations
|
| | Mergers generally require approval of a majority of all outstanding shares. | | | Statutory mergers require a special resolution, and any other authorization as may be specified in the relevant articles of association. Parties holding certain security interests in the constituent companies must also consent. | |
| | | Mergers in which less than 20% of the acquirer’s stock is issued generally do not require acquirer stockholder approval. | | | All statutory mergers (other than parent/subsidiary mergers) require shareholder approval by special resolution — there is no exception for smaller mergers. | |
| | | Mergers in which one corporation owns 90% or more of a second corporation may be completed without the vote of the second corporation’s board of directors or stockholders. | | | Where a bidder has acquired at least 90% of the shares to which a takeover offer relates, it can compulsorily acquire the shares of the remaining shareholders and thereby become the sole shareholder. A Cayman Islands company may also be acquired through a scheme of arrangement transaction which is approved by a majority in number representing 75% in value of shareholders present, in person or by proxy, at a shareholder meeting convened by the Cayman Islands court. Once shareholder approval has been obtained, the scheme of arrangement is then sanctioned by a Cayman Islands court. | |
Stockholder/Shareholder Votes for Routine Matters
|
| | Generally, approval of routine corporate matters that are put to a stockholder vote require the affirmative vote of the majority of shares present in person or represented by proxy at the meeting and entitled to vote on the subject matter. | | | Under the Cayman Islands Companies Act and the Current Articles, routine corporate matters may be approved by an ordinary resolution (being a resolution passed by a simple majority of the shareholders as being entitled to do so). | |
| | |
Delaware
|
| |
Cayman Islands
|
|
Appraisal Rights
|
| | Generally a stockholder of a publicly traded corporation does not have appraisal rights in connection with a merger, except in certain circumstances. | | | Minority shareholders that dissent from a merger are entitled to be paid the fair market value of their shares, which if necessary may ultimately be determined by the court. | |
Inspection of Books and Records
|
| | Any stockholder may inspect the corporation’s books and records for a proper purpose during the usual hours for business. | | | Shareholders generally do not have any rights to inspect or obtain copies of the register of shareholders or other corporate records of a company. | |
Stockholder/Shareholder Lawsuits
|
| | A stockholder may bring a derivative suit subject to procedural requirements (including adopting Delaware as the exclusive forum. | | | In the Cayman Islands, the decision to institute proceedings on behalf of a company is generally taken by the company’s board of directors. A shareholder may be entitled to bring a derivative action on behalf of the company, but only in certain limited circumstances. | |
Fiduciary Duties of Directors
|
| | Directors must exercise a duty of care and duty of loyalty and good faith to the company and its stockholders. | | | A director owes fiduciary duties to a company, including to avoid conflicts of interest and to exercise loyalty, honesty and good faith to the company as a whole. | |
| | | | | | In addition to fiduciary duties, directors owe a duty of care, diligence and skill. Such duties are owed to the company but may be owed direct to creditors or shareholders in certain limited circumstances. | |
Indemnification of Directors and Officers
|
| | A corporation is generally permitted to indemnify its directors and officers acting in good faith. | | | A Cayman Islands company generally may indemnify its directors or officers except with regard to fraud or willful default. | |
Limited Liability of Directors
|
| | Permits limiting or eliminating the monetary liability of a director to a corporation or its stockholders, except with regard to breaches of duty of loyalty, intentional misconduct, unlawful repurchases or dividends, or improper personal benefit. | | | Liability of directors may be eliminated, except with regard to their own fraud or willful default. | |
Advisory Charter Proposal
|
| |
HealthCor Current Articles
|
| |
Proposed Charter
|
|
Advisory Charter Proposal A — Changes in Share Capital
|
| | Under the Current Articles, HealthCor is currently authorized to issue 555,000,000 shares of capital stock, consisting of (a) 550,000,000 ordinary fully paid shares, including 500,000,000 Class A ordinary shares, par value $0.0001 each per share, and 50,000,000 Class B ordinary shares, par value $0.0001 each per share, and (b) 5,000,000 preference shares, par value $0.0001 each per share. | | | Under the Proposed Charter, New Hyperfine will be authorized to issue 628,000,000 shares of capital stock, consisting of (i) 600,000,000 shares of New Hyperfine Class A common stock, par value $0.0001 per share, (ii) 27,000,000 shares of New Hyperfine Class B common stock, par value $0.0001 per share, and (iii) 1,000,000 shares of preferred stock, par value $0.0001 per share. | |
Advisory Charter Proposal B — Voting Power
|
| | Under the Current Articles, the holders of Class A ordinary shares and Class B ordinary shares are entitled to one (1) vote for each such share on all matters which shareholders are entitled to vote. | | | Under the Proposed Charter, holders of New Hyperfine Class A common stock will be entitled to cast (1)one vote per share of New Hyperfine Class A common stock, while holders of New Hyperfine Class B common stock will be entitled to cast one (1) vote per share of New Hyperfine Class A common stock prior to the Effective Time and twenty (20) votes per share of New Hyperfine Class B common stock at and after the Effective Time. | |
Advisory Charter Proposal
|
| |
HealthCor Current Articles
|
| |
Proposed Charter
|
|
Advisory Charter Proposal C — Limiting the Ability to Act by Written Consent
|
| | The Current Articles provide that a resolution in writing signed by all of the shareholders entitled to vote at general meetings shall be as valid and effective as if the same had been passed at a duly convened and held general meeting. | | | Under the Proposed Charter, any action required or permitted to be taken by the stockholders of New Hyperfine must be effected at an annual or special meeting of the stockholders and may not be effected by written consent; provided, however, prior to the first date on which the issued and outstanding shares of New Hyperfine Class B common stock represent less than 50% of the voting power of the then outstanding shares of capital stock of New Hyperfine that would be entitled to vote for the election of directors, any action required or permitted to be taken at any annual or special meeting of New Hyperfine stockholders, may be taken by written consent if such written consent is signed by the holders of the outstanding stock having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares entitled to vote on such matter were present and voted. | |
Advisory Charter Proposal
|
| |
HealthCor Current Articles
|
| |
Proposed Charter
|
|
Advisory Charter Proposal D — Required Vote to Amend the Charter
|
| | The Current Articles provide that amendments may be made by a special resolution under the Cayman Islands Companies Act, being the affirmative vote of the holders of at least two-thirds of the ordinary shares who, being present in person or by proxy and entitled to vote, vote at a general meeting. | | |
Under the Proposed Charter, in addition to any vote required by Delaware law, the Proposed Charter may be amended, altered, changed, adopted or repealed by the affirmative vote of the holders of a majority of the voting power of all shares of capital stock then outstanding and entitled to vote generally in the election of directors, voting together as a single class; provided, however, that (i) so long as any shares of New Hyperfine Class B common stock remain outstanding, the affirmative vote of the holders of two-thirds (2/3) of the outstanding shares of New Hyperfine Class B common stock, voting as a separate class, is required to amend, alter, change, repeal or adopt any provisions of the Proposed Charter (1) in a manner that is inconsistent with, or that changes any of the voting, conversion, dividend or liquidation provisions of the shares of New Hyperfine Class B common stock or other rights, powers, preferences or privileges of the shares of Class B common stock, (2) to provide for each share of New Hyperfine Class A common stock or any
Preferred Stock to have more than one (1) vote per share or any rights to a separate class vote of the holders of shares of New Hyperfine Class A common stock other than as provided by the Proposed Charter or required by the DGCL, or (3) to otherwise adversely impact the rights, powers, preferences or privileges of the shares of New Hyperfine Class B common stock in a manner that is disparate from the manner in which it affects the rights, powers, preferences or privileges of the shares of New Hyperfine Class A common stock; and (ii) so long as any shares of New Hyperfine Class A common stock remain
|
|
Advisory Charter Proposal
|
| |
HealthCor Current Articles
|
| |
Proposed Charter
|
|
| | | | | | outstanding, the affirmative vote of the holders of a majority of the outstanding shares of New Hyperfine Class A common stock, voting as a separate class, is required to amend, alter, change, repeal or adopt any provisions of the Proposed Charter (1) in a manner that alters or changes the powers, preferences, or special rights of the shares of New Hyperfine Class A common stock so as to affect them adversely, or (2) to provide for each share of New Hyperfine Class B common stock to have more than twenty (20) votes per share or any rights to a separate class vote of the holders of shares of New Hyperfine Class B common stock other than as provided by the Proposed Charter or required by the DGCL. Any amendment to a provision of the Proposed Charter that contemplates a specific approval requirement by the stockholders shall require the greater of (x) the specific approval requirement by the stockholders contemplated in that provision and (y) the approval requirements contemplated in the provisions immediately above. | |
Advisory Charter Proposal
|
| |
HealthCor Current Articles
|
| |
Proposed Charter
|
|
Advisory Charter Proposal E — Required Vote to Amend the Bylaws
|
| | The Current Articles provide that amendments may be made by a special resolution under the Cayman Islands Companies Act, being the affirmative vote of the holders of at least two-thirds of the ordinary shares who, being present in person or by proxy and entitled to vote, vote at a general meeting. | | | Under the Proposed Charter, the New Hyperfine Board is expressly authorized to adopt, amend, alter or repeal the New Hyperfine Bylaws by the affirmative vote of a majority of the directors present at any regular or special meeting of the New Hyperfine Board at which a quorum is present. The New Hyperfine Bylaws may also be adopted, amended, altered or repealed, (i) on or after the time that the outstanding shares of Class B common stock represents less than 50% of the voting power of the shares of capital stock of New Hyperfine then outstanding and entitled to vote in the election of directors, by the affirmative vote of the holders of at least two-thirds (2/3) of the voting power of the capital stock of New Hyperfine or, prior to such time (ii) by the affirmative vote of the holders of a majority of the voting power of the capital stock of New Hyperfine then outstanding and entitled to vote in the election of directors. | |
Advisory Charter Proposal F — Required Vote to Change Number of Directors
|
| | Under the Current Articles, the number of directors of HealthCor may be increased or reduced by an ordinary resolution, being the affirmative vote of the holders of a majority of the ordinary shares who, being present either in person or by proxy and entitled to vote, vote at a general meeting. | | |
Under the Proposed Charter, the number of directors will be fixed from time to time by the New Hyperfine Board; provided that, unless approved (i) when outstanding Class B common stock represents less than 50% of the voting power of the then outstanding shares of capital stock of New Hyperfine that would be entitled to vote for the election of directors, by the affirmative vote of the holders of at least two-thirds (2/3) of the voting power of the capital stock of New Hyperfine or, prior to such time (ii) by the affirmative vote of the holders of a majority of the voting power of the outstanding capital stock of New
Hyperfine, the number of directors shall not exceed nine (9).
|
|
Advisory Charter Proposal
|
| |
HealthCor Current Articles
|
| |
Proposed Charter
|
|
Advisory Charter Proposal G — Classified Board
|
| | Under the Current Articles, the HealthCor board of directors shall be divided into three classes, nearly equal in number as possible and designated as Class I, Class II and Class III. The Class I directors shall stand appointed for a term expiring at HealthCor’s first annual general meeting, the Class II directors shall stand appointed for a term expiring at the HealthCor’s second annual general meeting and the Class III directors shall stand appointed for a term expiring at the HealthCor’s third annual general meeting. Commencing at the HealthCor’s first annual general meeting, and at each annual general meeting thereafter, directors appointed to succeed those directors whose terms expire shall be appointed for a term of office to expire at the third succeeding annual general meeting after their appointment. | | | Under the Proposed Charter, all directors will be elected each year for one-year terms. | |
Advisory Charter Proposal
|
| |
HealthCor Current Articles
|
| |
Proposed Charter
|
|
Advisory Charter Proposal H — Removal of Directors; Newly-Created Directorships
|
| |
Under the Current Articles, prior to the closing of a business combination, holders of the Class B ordinary shares of HealthCor have the exclusive right to remove any director of HealthCor and holders of Class A ordinary shares of HealthCor have no right to vote on the removal of any director. Following the closing of a business combination, directors of HealthCor may be removed by the affirmative vote of holders of a majority of the voting power of all then outstanding shares of capital stock of HealthCor.
Newly-created directorships resulting from the increase in the number of directors and any vacancies on the HealthCor board of directors may be filled by (i) prior to the closing of a business combination, the affirmative vote of holders of a majority of the Class B ordinary shares of HealthCor, (ii) following the closing of a business combination, the affirmative vote of holders of a majority of the voting power of all then outstanding shares of capital stock of HealthCor or (iii) at any time, an affirmative vote of the majority of the remaining directors then in office.
|
| |
Under the Proposed Charter, any or all directors of New Hyperfine may be removed from office at any time with or without cause and for any or no reason only with and immediately upon the vote, (i) on or after the time that the outstanding shares of Class B common stock represents less than 50% of the voting power of the shares of capital stock of New Hyperfine then outstanding and entitled to vote in the election of directors, by the affirmative vote of the holders of at least two-thirds (2/3) of the voting power of the capital stock of New Hyperfine or, prior to such time, (ii) by the affirmative vote of the holders of a majority of the voting power of the capital stock of New Hyperfine then outstanding and entitled to vote in the election of directors.
Newly-created directorships resulting from an increase in the number of directors and any vacancies on the New Hyperfine Board may be filled by either the directors of the New Hyperfine Board, or by the New Hyperfine stockholders as set forth in the Proposed Charter.
|
|
Advisory Charter Proposal I — Removal of Blank Check Company Provisions
|
| | The Current Articles contains various provisions applicable only to blank check companies. | | | The Proposed Charter will not include these provisions applicable only to blank check companies, including the provisions requiring that HealthCor have net tangible assets of at least $5,000,001 immediately prior to, or upon such consummation of, a business combination. | |
| | |
HealthCor
(Historical) |
| |
Hyperfine and
Liminal (Historical) |
| |
No redemption scenario
|
| |
Maximum redemption scenario
|
| ||||||||||||||||||||||||||||||
|
Transaction
Accounting Adjustments |
| |
Note 3
|
| |
Pro Forma
|
| |
Transaction
Accounting Adjustments |
| |
Note 3
|
| |
Pro Forma
|
| ||||||||||||||||||||||||||
Assets
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Current assets: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Cash and cash equivalents
|
| | | $ | 526 | | | | | $ | 65,475 | | | | | $ | 311,285 | | | |
(a), (b)
|
| | | $ | 377,286 | | | | | $ | 104,285 | | | |
(a), (b)
|
| | | $ | 170,286 | | |
Restricted cash
|
| | | | — | | | | | | 3,467 | | | | | | — | | | | | | | | | 3,467 | | | | | | — | | | | | | | | | 3,467 | | |
Accounts receivable
|
| | | | — | | | | | | 940 | | | | | | — | | | | | | | | | 940 | | | | | | — | | | | | | | | | 940 | | |
Unbilled receivables
|
| | | | — | | | | | | 48 | | | | | | — | | | | | | | | | 48 | | | | | | — | | | | | | | | | 48 | | |
Inventory
|
| | | | — | | | | | | 2,763 | | | | | | — | | | | | | | | | 2,763 | | | | | | — | | | | | | | | | 2,763 | | |
Prepaid expenses and other current assets
|
| | | | 402 | | | | | | 3,600 | | | | | | (3,042) | | | |
(b)
|
| | | | 960 | | | | | | (3,042) | | | |
(b)
|
| | | | 960 | | |
Due from related parties
|
| | | | — | | | | | | 13 | | | | | | — | | | | | | | | | 13 | | | | | | — | | | | | | | | | 13 | | |
Total Current Assets
|
| | | | 928 | | | | | | 76,306 | | | | | | 308,243 | | | | | | | | | 385,477 | | | | | | 101,243 | | | | | | | | | 178,477 | | |
Property and equipment
|
| | | | — | | | | | | 3,325 | | | | | | — | | | | | | | | | 3,325 | | | | | | — | | | | | | | | | 3,325 | | |
Other assets – related party
|
| | | | — | | | | | | 1,086 | | | | | | — | | | | | | | | | 1,086 | | | | | | — | | | | | | | | | 1,086 | | |
Net investment in lease
|
| | | | — | | | | | | 37 | | | | | | — | | | | | | | | | 37 | | | | | | — | | | | | | | | | 37 | | |
Other long term assets
|
| | | | — | | | | | | 614 | | | | | | — | | | | | | | | | 614 | | | | | | — | | | | | | | | | 614 | | |
Marketable securities held in Trust Account
|
| | | | 207,014 | | | | | | — | | | | | | (207,014) | | | |
(c)
|
| | | | — | | | | | | (207,014) | | | |
(c)
|
| | | | — | | |
Total Assets
|
| | | $ | 207,942 | | | | | $ | 81,368 | | | | | $ | 101,229 | | | | | | | | $ | 390,539 | | | | | $ | (105,771) | | | | | | | | $ | 183,539 | | |
Liabilities, commitments and contingencies and stockholders’ equity (deficit)
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Current liabilities: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Accounts payable
|
| | | | — | | | | | | 4,945 | | | | | | — | | | | | | | | | 4,945 | | | | | | — | | | | | | | | | 4,945 | | |
Deferred grant funding
|
| | | | — | | | | | | 3,467 | | | | | | — | | | | | | | | | 3,467 | | | | | | — | | | | | | | | | 3,467 | | |
Deferred revenue
|
| | | | — | | | | | | 774 | | | | | | — | | | | | | | | | 774 | | | | | | — | | | | | | | | | 774 | | |
Due to related parties
|
| | | | — | | | | | | 1,334 | | | | | | — | | | | | | | | | 1,334 | | | | | | — | | | | | | | | | 1,334 | | |
Accrued expenses and other current liabilities
|
| | | | 1,938 | | | | | | 3,294 | | | | | | (2,115) | | | |
(a), (b)
|
| | | | 3,117 | | | | | | (2,115) | | | | | | | | | 3,117 | | |
Accrued offering costs
|
| | | | 8 | | | | | | — | | | | | | (8) | | | |
(a)
|
| | | | — | | | | | | (8) | | | |
(a)
|
| | | | — | | |
Total Current Liabilities
|
| | | | 1,946 | | | | | | 13,814 | | | | | | (2,123) | | | | | | | | | 13,637 | | | | | | (2,123) | | | | | | | | | 13,637 | | |
Deferred underwriting fee payable
|
| | | | 7,245 | | | | | | — | | | | | | (7,245) | | | |
(b)
|
| | | | — | | | | | | (7,245) | | | |
(b)
|
| | | | — | | |
Long term notes payable
|
| | | | — | | | | | | 178 | | | | | | (178) | | | |
(d)
|
| | | | — | | | | | | (178) | | | |
(d)
|
| | | | — | | |
Long term deferred revenue
|
| | | | — | | | | | | 340 | | | | | | — | | | | | | | | | 340 | | | | | | — | | | | | | | | | 340 | | |
Total Liabilities
|
| | | | 9,191 | | | | | | 14,332 | | | | | | (9,546) | | | | | | | | | 13,977 | | | | | | (9,546) | | | | | | | | | 13,977 | | |
Common stock
|
| | | | 207,000 | | | | | | — | | | | | | (207,000) | | | |
(e)
|
| | | | — | | | | | | (207,000) | | | |
(e)
|
| | | | — | | |
Hyperfine Convertible preferred stock
|
| | | | — | | | | | | 158,747 | | | | | | (158,747) | | | |
(e)
|
| | | | — | | | | | | (158,747) | | | |
(e)
|
| | | | — | | |
Liminal Convertible preferred stock
|
| | | | — | | | | | | 9,350 | | | | | | (9,350) | | | |
(e)
|
| | | | — | | | | | | (9,350) | | | |
(e)
|
| | | | — | | |
Stockholder’s equity | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Hyperfine common stock
|
| | | | — | | | | | | 1 | | | | | | (1) | | | |
(e)
|
| | | | | | | | | | (1) | | | |
(e)
|
| | | | — | | |
Liminal common stock
|
| | | | — | | | | | | — | | | | | | — | | | |
(e)
|
| | | | — | | | | | | — | | | |
(e)
|
| | | | — | | |
Special-voting common stock
|
| | | | — | | | | | | — | | | | | | — | | | |
(e)
|
| | | | — | | | | | | — | | | |
(e)
|
| | | | — | | |
Class A ordinary shares
|
| | | | — | | | | | | — | | | | | | 7 | | | |
(e)
|
| | | | 7 | | | | | | 5 | | | |
(e)
|
| | | | 5 | | |
Class B ordinary shares
|
| | | | 1 | | | | | | — | | | | | | 1 | | | |
(e)
|
| | | | 2 | | | | | | 1 | | | |
(e)
|
| | | | 2 | | |
Additional paid-in capital
|
| | | | — | | | | | | 9,173 | | | | | | 481,818 | | | |
(e)
|
| | | | 490,991 | | | | | | 274,820 | | | |
(e)
|
| | | | 283,993 | | |
Accumulated deficit
|
| | | | (8,250) | | | | | | (110,235) | | | | | | 4,047 | | | |
(e)
|
| | | | (114,438) | | | | | | 4,047 | | | |
(e)
|
| | | | (114,438) | | |
Total stockholders’ equity (deficit)
|
| | | | (8,249) | | | | | | (101,061) | | | | | | 485,872 | | | | | | | | | 376,562 | | | | | | 278,872 | | | | | | | | | 169,562 | | |
Total liabilities, commitments and contingencies and stockholders’ equity (deficit)
|
| | | $ | 207,942 | | | | | $ | 81,368 | | | | | $ | 101,229 | | | | | | | | $ | 390,539 | | | | | $ | (105,771) | | | | | | | | $ | 183,539 | | |
| | |
HealthCor
(Historical) |
| |
Hyperfine and
Liminal (Historical) |
| |
No redemption scenario
|
| |
Maximum redemption scenario
|
| ||||||||||||||||||||||||||||||
|
Transaction
Accounting Adjustments |
| |
Note 3
|
| |
Pro Forma
|
| |
Transaction
Accounting Adjustments |
| |
Note 3
|
| |
Pro Forma
|
| ||||||||||||||||||||||||||
Sales | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Device
|
| | | $ | — | | | | | $ | 521 | | | | | | — | | | | | | | | $ | 521 | | | | | | — | | | | | | | | $ | 521 | | |
Services
|
| | | | — | | | | | | 539 | | | | | | — | | | | | | | | | 539 | | | | | | — | | | | | | | | | 539 | | |
Total sales
|
| | | | — | | | | | | 1,060 | | | | | | — | | | | | | | | | 1,060 | | | | | | — | | | | | | | | | 1,060 | | |
Cost of sales
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Device
|
| | | | — | | | | | | 1,420 | | | | | | — | | | | | | | | | 1,420 | | | | | | — | | | | | | | | | 1,420 | | |
Services
|
| | | | — | | | | | | 354 | | | | | | — | | | | | | | | | 354 | | | | | | — | | | | | | | | | 354 | | |
Total cost of sales
|
| | | | — | | | | | | 1,774 | | | | | | — | | | | | | | | | 1,774 | | | | | | — | | | | | | | | | 1,774 | | |
Gross margin
|
| | | | — | | | | | | (714) | | | | | | — | | | | | | | | | (714) | | | | | | — | | | | | | | | | (714) | | |
Operating expenses | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Research and development
|
| | | | — | | | | | | 16,949 | | | | | | 401 | | | |
(f)
|
| | | | 17,350 | | | | | | 401 | | | |
(f)
|
| | | | 17,350 | | |
General and administrative
|
| | | | — | | | | | | 15,348 | | | | | | 1,788 | | | |
(f), (h)
|
| | | | 17,136 | | | | | | 1,788 | | | |
(f), (h)
|
| | | | 17,136 | | |
Sales and marketing
|
| | | | — | | | | | | 5,770 | | | | | | 26 | | | |
(f)
|
| | | | 5,796 | | | | | | 26 | | | |
(f)
|
| | | | 5,796 | | |
Operating and formation costs
|
| | | | 2,494 | | | | | | — | | | | | | — | | | | | | | | | 2,494 | | | | | | — | | | | | | | | | 2,494 | | |
Total operating expenses
|
| | | | 2,494 | | | | | | 38,067 | | | | | | 2,215 | | | | | | | | | 42,776 | | | | | | 2,215 | | | | | | | | | 42,776 | | |
Loss from operations
|
| | | | (2,494) | | | | | | (38,781) | | | | | | (2,215) | | | | | | | | | (43,490) | | | | | | (2,215) | | | | | | | | | (43,490) | | |
Interest income
|
| | | | — | | | | | | 13 | | | | | | — | | | | | | | | | 13 | | | | | | — | | | | | | | | | 13 | | |
Other income, net
|
| | | | — | | | | | | 2 | | | | | | — | | | | | | | | | 2 | | | | | | — | | | | | | | | | 2 | | |
Interest earned on marketable securities held in Trust
account |
| | | | 14 | | | | | | — | | | | | | (14) | | | |
(k)
|
| | | | — | | | | | | (14) | | | |
(k)
|
| | | | — | | |
Loss before provision for income taxes
|
| | | | (2,480) | | | | | | (38,766) | | | | | | (2,229) | | | | | | | | | (43,475) | | | | | | (2,229) | | | | | | | | | (43,475) | | |
Provision for income tax
|
| | | | — | | | | | | — | | | | | | — | | | |
(l)
|
| | | | — | | | | | | — | | | |
(l)
|
| | | | — | | |
Net loss and comprehensive loss
|
| | | | (2,480) | | | | | | (38,766) | | | | | | (2,229) | | | | | | | | | (43,475) | | | | | | (2,229) | | | | | | | | | (43,475) | | |
Net loss per share
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Basic and diluted weighted average shares outstanding, Class A Ordinary shares subject to possible redemption
|
| | | | 18,501,099 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Basic and diluted net loss per share, Class A Ordinary shares subject to possible redemption
|
| | | $ | (0.10) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Basic and diluted weighted average shares outstanding
|
| | | | 548,777 | | | | | | 5,229,877 | | | | | | | | | |
(m)
|
| | | | 87,220,452 | | | | | | | | | |
(m)
|
| | | | 66,520,452 | | |
Basic and diluted net loss per share(1)
|
| | | $ | (0.10) | | | | | $ | (7.41) | | | | | | | | | |
(m)
|
| | | $ | (0.50) | | | | | | | | | |
(m)
|
| | | $ | (0.65) | | |
Basic and diluted weighted average shares outstanding, Class B Ordinary shares not subject to possible redemption
|
| | | | 5,103,297 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Basic and diluted net loss per share, Class B Ordinary
shares not subject to possible redemption |
| | | $ | (0.10) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | |
HealthCor
(Historical) |
| |
Hyperfine and
Liminal (Historical) |
| |
No redemption scenario
|
| |
Maximum redemption scenario
|
| ||||||||||||||||||||||||||||||
|
Transaction
Accounting Adjustments |
| |
Note 3
|
| |
Pro Forma
|
| |
Transaction
Accounting Adjustments |
| |
Note 3
|
| |
Pro Forma
|
| ||||||||||||||||||||||||||
Sales | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Device
|
| | | $ | — | | | | | $ | 200 | | | | | | — | | | | | | | | $ | 200 | | | | | | — | | | | | | | | $ | 200 | | |
Services
|
| | | | — | | | | | | 94 | | | | | | — | | | | | | | | | 94 | | | | | | — | | | | | | | | | 94 | | |
Total sales
|
| | | | — | | | | | | 294 | | | | | | — | | | | | | | | | 294 | | | | | | — | | | | | | | | | 294 | | |
Cost of sales | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Device
|
| | | | — | | | | | | 763 | | | | | | — | | | | | | | | | 763 | | | | | | — | | | | | | | | | 763 | | |
Services
|
| | | | — | | | | | | 8 | | | | | | — | | | | | | | | | 8 | | | | | | — | | | | | | | | | 8 | | |
Total cost of sales
|
| | | | — | | | | | | 771 | | | | | | — | | | | | | | | | 771 | | | | | | — | | | | | | | | | 771 | | |
Gross margin
|
| | | | — | | | | |
|
(477)
|
| | | | | — | | | | | | | |
|
(477)
|
| | | | | — | | | | | | | |
|
(477)
|
| |
Operating expenses | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Research and development
|
| | | | — | | | | | | 14,593 | | | | | | 535 | | | |
(f)
|
| | | | 15,128 | | | | | | 535 | | | |
(f)
|
| | | | 15,128 | | |
General and administrative
|
| | | | — | | | | | | 5,921 | | | | | | 6,588 | | | |
(f), (g), (h), (i), (j)
|
| | | | 12,509 | | | | | | 6,588 | | | |
(f), (g), (h), (i), (j)
|
| | | | 12,509 | | |
Sales and marketing
|
| | | | — | | | | | | 2,500 | | | | | | 35 | | | |
(f)
|
| | | | 2,535 | | | | | | 35 | | | |
(f)
|
| | | | 2,535 | | |
Formation and operating costs
|
| | | | 5 | | | | | | — | | | | | | — | | | | | | | | | 5 | | | | | | — | | | | | | | | | 5 | | |
Total operating expenses
|
| | | | 5 | | | | | | 23,014 | | | | | | 7,158 | | | | | | | | | 30,177 | | | | | | 7,158 | | | | | | | | | 30,177 | | |
Loss from operations
|
| | | | (5) | | | | | | (23,491) | | | | | | (7,158) | | | | | | | | | (30,654) | | | | | | (7,158) | | | | | | | | | (30,654) | | |
Interest income
|
| | | | — | | | | | | 70 | | | | | | — | | | | | | | | | 70 | | | | | | — | | | | | | | | | 70 | | |
Other income (expense), net
|
| | | | — | | | | | | (6) | | | | | | — | | | | | | | | | (6) | | | | | | — | | | | | | | | | (6) | | |
Loss before provision for income
taxes |
| | | | (5) | | | | | | (23,427) | | | | | | (7,158) | | | | | | | | | (30,590) | | | | | | (7,158) | | | | | | | | | (30,590) | | |
Provision for income tax
|
| | | | — | | | | | | — | | | | | | — | | | |
(l)
|
| | | | — | | | | | | — | | | |
(k)
|
| | | | — | | |
Net loss and comprehensive
loss |
| | | | (5) | | | | | | (23,427) | | | | | | (7,158) | | | | | | | | | (30,590) | | | | | | (7,158) | | | | | | | | | (30,590) | | |
Net loss per share | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Basic and diluted weighted average
shares outstanding |
| | | | 4,500,000 | | | | | | 4,651,127 | | | | | | | | | |
(m)
|
| | | | 87,220,452 | | | | | | | | | |
(m)
|
| | | | 66,520,452 | | |
Basic and diluted net loss per share(1)
|
| | | $ | (0.00) | | | | | $ | (5.04) | | | | | | | | | |
(m)
|
| | | $ | (0.35) | | | | | | | | | |
(m)
|
| | | $ | (0.46) | | |
| | |
Class A
|
| |
Class B
|
| |
Total pre-Business
Combination |
| |||||||||
HealthCor Stockholders
|
| | | | 20,700,000 | | | | | | — | | | | | | 20,700,000 | | |
Parent Sponsor
|
| | | | 614,000 | | | | | | 5,070,000 | | | | | | 5,684,000 | | |
Other Initial Stockholders
|
| | | | — | | | | | | 105,000 | | | | | | 105,000 | | |
Total
|
| | | | 21,314,000 | | | | | | 5,175,000 | | | | | | 26,489,000 | | |
| | |
No redemption scenario
|
| |
Maximum redemption scenario
|
| ||||||||||||||||||||||||||||||
| | |
Shares
|
| |
Ownership,
% |
| |
Voting rights,
% |
| |
Shares
|
| |
Ownership,
% |
| |
Voting rights,
% |
| ||||||||||||||||||
Hyperfine Stockholders
|
| | | | 37,840,567 | | | | | | 43.4% | | | | | | 51.9% | | | | | | 37,840,567 | | | | | | 56.9% | | | | | | 54.9% | | |
Liminal Stockholders
|
| | | | 10,280,885 | | | | | | 11.8% | | | | | | 37.6% | | | | | | 10,280,885 | | | | | | 15.4% | | | | | | 39.9% | | |
HealthCor Stockholders
|
| | | | 20,700,000 | | | | | | 23.7% | | | | | | 5.6% | | | | | | — | | | | | | — | | | | | | — | | |
Parent Sponsor
|
| | | | 5,684,000 | | | | | | 6.5% | | | | | | 1.5% | | | | | | 5,684,000 | | | | | | 8.5% | | | | | | 1.6% | | |
Other Initial Stockholders
|
| | | | 105,000 | | | | | | 0.1% | | | | | | 0.0% | | | | | | 105,000 | | | | | | 0.2% | | | | | | 0.0% | | |
PIPE Investors
|
| | | | 12,610,000 | | | | | | 14.5% | | | | | | 3.4% | | | | | | 12,610,000 | | | | | | 19.0% | | | | | | 3.6% | | |
Closing Shares
|
| | |
|
87,220,452
|
| | | |
|
100%
|
| | | |
|
100%
|
| | | |
|
66,520,452
|
| | | |
|
100%
|
| | | |
|
100%
|
| |
| | |
Note
|
| |
No redemption
scenario |
| |
Maximum
redemption scenario |
| |||||||||
HealthCor cash and cash equivalents as of September 30, 2021 – pre Business Combination
|
| | | | | | | | | $ | 526 | | | | | $ | 526 | | |
Hyperfine and Liminal cash and cash equivalents as of September 30, 2021 – pre Business Combination
|
| | | | | | | | | | 65,475 | | | | | | 65,475 | | |
Total pre Business Combination
|
| | | | | | | | | | 66,001 | | | | | | 66,001 | | |
HealthCor cash and securities held in Trust Account
|
| | | | (1) | | | | | | 207,014 | | | | | | 207,014 | | |
PIPE Financing
|
| | | | (2) | | | | | | 126,100 | | | | | | 126,100 | | |
Payment to redeeming Public Stockholders
|
| | | | (3) | | | | | | — | | | | | | (207,000) | | |
Payment of notes payable
|
| | | | (4) | | | | | | (178) | | | | | | (178) | | |
Payment of accrued offering costs
|
| | | | (5) | | | | | | (8) | | | | | | (8) | | |
Payment of deferred underwriting fees
|
| | | | (6) | | | | | | (7,245) | | | | | | (7,245) | | |
Payment of accrued HealthCor transaction costs
|
| | | | (7) | | | | | | (1,609) | | | | | | (1,609) | | |
Payment of accrued Hyperfine transaction costs
|
| | | | (8) | | | | | | (506) | | | | | | (506) | | |
Payment of other transaction costs and additional costs
|
| | | | (9) | | | | | | (11,033) | | | | | | (11,033) | | |
Payment of management bonus at the close of Business Combination
|
| | | | (10) | | | | | | (1,250) | | | | | | (1,250) | | |
Total Business Combination adjustments
|
| | | | | | | | | | 311,285 | | | | | | 104,285 | | |
Post-Business Combination cash and cash equivalents balance
|
| | | | | | | | | $ | 377,286 | | | | | $ | 170,286 | | |
| | |
Note
|
| |
HealthCor / Combined
Company common stock |
| |
Hyperfine
Common stock |
| |
Additional
paid-in capital |
| |
Accumulated
deficit |
| |
Total
stockholders’ equity (deficit) |
| | |
HealthCor
Temporary equity |
| |
Hyperfine
Temporary equity |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Class A
|
| |
Class B
|
| | | | | | | | | | | | | |
Class A
common stock subject to possible redemption |
| |
Hyperfine
Convertible preferred stock |
| |
Liminal
Convertible preferred stock |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Shares
|
| |
Amounts
|
| |
Shares
|
| |
Amounts
|
| |
Shares
|
| |
Amounts
|
| |
Shares
|
| |
Amounts
|
| |
Shares
|
| |
Amounts
|
| |
Shares
|
| |
Amounts
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
HealthCor equity as of September 30. 2021 – pre Business Combination
|
| | | | | | | — | | | | | $ | — | | | | | | 5,175,000 | | | | | $ | 1 | | | | | | — | | | | | $ | — | | | | | $ | — | | | | | $ | (8,250) | | | | | $ | (8,249) | | | | | | | 20,700,000 | | | | | $ | 207,000 | | | | | | 109,182,191 | | | | | $ | 158,747 | | | | | | 57,500,000 | | | | | $ | 9,350 | | |
HealthCor equity as of September 30. 2021 – pre Business Combination – Initial Stockholders
|
| | | | | | | 614,000 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Hyperfine and Liminal equity as of September 30, 2021 – pre Business Combination
|
| | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 6,503,073 | | | | | | 1 | | | | | | 9,173 | | | | | | (110,235) | | | | | $ | (101,061) | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Total equity as of September 30, 2021 – Pre Business Combination
|
| | | | | | | 614,000 | | | | | | — | | | | | | 5,175,000 | | | | | | 1 | | | | | | 6,503,073 | | | | | | 1 | | | | | | 9,173 | | | | | | (118,485) | | | | | | (109,310) | | | | | | | 20,700,000 | | | | | | 207,000 | | | | | | 109,182,191 | | | | | | 158,747 | | | | | | 57,500,000 | | | | | | 9,350 | | |
Transaction Accounting adjustments:
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Reclassification of HealthCor’s redeemable shares to Class A common stock
|
| | | | | | | 20,700,000 | | | | | | 2 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 206,998 | | | | | | — | | | | | | 207,000 | | | | | | | (20,700,000) | | | | | | (207,000) | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Initial Stockholders
|
| | | | | | | 5,175,000 | | | | | | 1 | | | | | | (5,175,000) | | | | | | (1) | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
PIPE Investors
|
| |
3(a)(2)
|
| | | | 12,610,000 | | | | | | 1 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 126,099 | | | | | | — | | | | | | 126,100 | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Shares issued to Hyperfine Stockholders as consideration
|
| | | | | | | 29,663,067 | | | | | | 3 | | | | | | 8,177,500 | | | | | | 1 | | | | | | — | | | | | | — | | | | | | (4) | | | | | | — | | | | | | — | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Shares issued to Liminal Stockholders as consideration
|
| | | | | | | 3,443,689 | | | | | | — | | | | | | 6,837,196 | | | | | | 1 | | | | | | — | | | | | | — | | | | | | (1) | | | | | | — | | | | | | — | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Incremental business combination
costs |
| |
3(b)(4)
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (10,838) | | | | | | (195) | | | | | | (11,033) | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Management bonus paid at the close of Business Combination
|
| |
3(a)(10), 3(i)
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (1,250) | | | | | | (1,250) | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Hyperfine capitalized expenses related to the business combination
|
| |
3(b)(5)
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (3,042) | | | | | | — | | | | | | (3,042) | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Elimination of historical accumulated deficit of
HealthCor |
| | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (8,250) | | | | | | 8,250 | | | | | | — | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Elimination of historical Hyperfine
common stock |
| | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (6,503,073) | | | | | | (1) | | | | | | 1 | | | | | | — | | | | | | — | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Elimination of historical Hyperfine
convertible preferred stock |
| | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 158,747 | | | | | | — | | | | | | 158,747 | | | | | | | — | | | | | | — | | | | | | (109,182,191) | | | | | | (158,747) | | | | | | — | | | | | | — | | |
| | |
Note
|
| |
HealthCor / Combined
Company common stock |
| |
Hyperfine
Common stock |
| |
Additional
paid-in capital |
| |
Accumulated
deficit |
| |
Total
stockholders’ equity (deficit) |
| | |
HealthCor
Temporary equity |
| |
Hyperfine
Temporary equity |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Class A
|
| |
Class B
|
| | | | | | | | | | | | | |
Class A
common stock subject to possible redemption |
| |
Hyperfine
Convertible preferred stock |
| |
Liminal
Convertible preferred stock |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Shares
|
| |
Amounts
|
| |
Shares
|
| |
Amounts
|
| |
Shares
|
| |
Amounts
|
| |
Shares
|
| |
Amounts
|
| |
Shares
|
| |
Amounts
|
| |
Shares
|
| |
Amounts
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Elimination of historical Liminal convertible preferred stock
|
| | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 9,350 | | | | | | — | | | | | | 9,350 | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (57,500,000) | | | | | | (9,350) | | |
Vesting of equity awards at the Closing of the Business Combination
|
| |
3(g)
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 258 | | | | | | (258) | | | | | | — | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Vesting of CEO restricted
stock units at the Closing of the Business Combination |
| |
3(h)(1)
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 2,500 | | | | | | (2,500) | | | | | | — | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Total Business Combination adjustments
|
| | | | | | | 71,591,756 | | | | | | 7 | | | | | | 9,839,696 | | | | | | 1 | | | | | | (6,503,073) | | | | | | (1) | | | | | | 481,818 | | | | | | 4,047 | | | | | | 485,872 | | | | | | | (20,700,000) | | | | | | (207,000) | | | | | | (109,182,191) | | | | | | (158,747) | | | | | | (57,500,000) | | | | | | (9,350) | | |
Post-Business Combination equity balance
|
| | | | | | | 72,205,756 | | | | | $ | 7 | | | | | | 15,014,696 | | | | | $ | 2 | | | | | | — | | | | | $ | — | | | | | $ | 490,991 | | | | | $ | (114,438) | | | | | $ | 376,562 | | | | | | | — | | | | | $ | — | | | | | | — | | | | | $ | — | | | | | | — | | | | | $ | — | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | |
HealthCor / Combined
Company common stock |
| |
Hyperfine
Common stock |
| | | | | | | | | | | | | | | | | | | | |
HealthCor
Temporary equity |
| |
Hyperfine
Temporary equity |
| | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | | |
Class A
|
| |
Class B
|
| |
Shares
|
| |
Amounts
|
| |
Additional
paid-in capital |
| |
Accumulated
deficit |
| |
Total
stockholders’ equity (deficit) |
| | |
Class A
common stock subject to possible redemption |
| |
Hyperfine
Convertible preferred stock |
| |
Liminal
Convertible preferred stock |
| | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | |
Note
|
| |
Shares
|
| |
Amounts
|
| |
Shares
|
| |
Amounts
|
| |
Shares
|
| |
Amounts
|
| |
Shares
|
| |
Amounts
|
| |
Shares
|
| |
Amounts
|
| | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
HealthCor equity as of September 30.
2021 – pre Business Combination |
| | | | | | | — | | | | | $ | — | | | | | | 5,175,000 | | | | | $ | 1 | | | | | | — | | | | | $ | — | | | | | $ | — | | | | | $ | (8,250) | | | | | $ | (8,249) | | | | | | | 20,700,000 | | | | | $ | 207,000 | | | | | | 109,182,191 | | | | | $ | 158,747 | | | | | | 57,500,000 | | | | | $ | 9,350 | | | | | |
HealthCor equity as of September 30.
2021 – pre Business Combination – Initial Stockholders |
| | | | | | | 614,000 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | ||
Hyperfine and Liminal equity as of
September 30, 2021 – pre Business Combination |
| | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 6,503,073 | | | | | | 1 | | | | | | 9,173 | | | | | | (110,235) | | | | | $ | (101,061) | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | |
Total equity as of September 30, 2021 – Pre Business Combination
|
| | | | | | | 614,000 | | | | | | — | | | | | | 5,175,000 | | | | | | 1 | | | | | | 6,503,073 | | | | | | 1 | | | | | | 9,173 | | | | | | (118,485) | | | | | | (109,310) | | | | | | | 20,700,000 | | | | | | 207,000 | | | | | | 109,182,191 | | | | | | 158,747 | | | | | | 57,500,000 | | | | | | 9,350 | | | | | |
Transaction Accounting adjustments:
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Reclassification of HealthCor’s redeemable shares to Class A common stock
|
| | | | | | | 20,700,000 | | | | | | 2 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 206,998 | | | | | | — | | | | | | 207,000 | | | | | | | (20,700,000) | | | | | | (207,000) | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | |
Initial Stockholders
|
| | | | | | | 5,175,000 | | | | | | 1 | | | | | | (5,175,000) | | | | | | (1) | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | |
Less: Redemption of redeemable
stock |
| |
3(a)(3)
|
| | | | (20,700,000) | | | | | | (2) | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (206,998) | | | | | | — | | | | | | (207,000) | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | |
PIPE Investors
|
| |
3(a)(2)
|
| | | | 12,610,000 | | | | | | 1 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 126,099 | | | | | | — | | | | | | 126,100 | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | |
Shares issued to Hyperfine Stockholders as consideration
|
| | | | | | | 29,663,067 | | | | | | 3 | | | | | | 8,177,500 | | | | | | 1 | | | | | | — | | | | | | — | | | | | | (4) | | | | | | — | | | | | | — | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | |
Shares issued to Liminal Stockholders as consideration
|
| | | | | | | 3,443,689 | | | | | | — | | | | | | 6,837,196 | | | | | | 1 | | | | | | — | | | | | | — | | | | | | (1) | | | | | | — | | | | | | — | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | |
Incremental business combination costs
|
| |
3(b)(4)
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (10,838) | | | | | | (195) | | | | | | (11,033) | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | |
Management bonus paid at the
close of Business Combination |
| |
3(a)(10), 3(i)
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (1,250) | | | | | | (1,250) | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | |
Hyperfine capitalized expenses related to the business combination
|
| |
3(b)(5)
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (3,042) | | | | | | — | | | | | | (3,042) | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | |
| | |
HealthCor / Combined
Company common stock |
| |
Hyperfine
Common stock |
| | | | | | | | | | | | | | | | | | | | |
HealthCor
Temporary equity |
| |
Hyperfine
Temporary equity |
| | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | | |
Class A
|
| |
Class B
|
| |
Shares
|
| |
Amounts
|
| |
Additional
paid-in capital |
| |
Accumulated
deficit |
| |
Total
stockholders’ equity (deficit) |
| | |
Class A
common stock subject to possible redemption |
| |
Hyperfine
Convertible preferred stock |
| |
Liminal
Convertible preferred stock |
| | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | |
Note
|
| |
Shares
|
| |
Amounts
|
| |
Shares
|
| |
Amounts
|
| |
Shares
|
| |
Amounts
|
| |
Shares
|
| |
Amounts
|
| |
Shares
|
| |
Amounts
|
| | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Elimination of historical accumulated deficit of HealthCor
|
| | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (8,250) | | | | | | 8,250 | | | | | | — | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | |
Elimination of historical Hyperfine common stock
|
| | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (6,503,073) | | | | | | (1) | | | | | | 1 | | | | | | — | | | | | | — | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | |
Elimination of historical
Hyperfine convertible preferred stock |
| | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 158,747 | | | | | | — | | | | | | 158,747 | | | | | | | — | | | | | | — | | | | | | (109,182,191) | | | | | | (158,747) | | | | | | — | | | | | | — | | | | | |
Elimination of historical Liminal
convertible preferred stock |
| | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 9,350 | | | | | | — | | | | | | 9,350 | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (57,500,000) | | | | | | (9,350) | | | | | |
Vesting of equity awards at the Closing of the Business Combination
|
| |
3(g)
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 258 | | | | | | (258) | | | | | | — | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | |
Vesting of CEO restricted stock units at the Closing of the Business Combination
|
| |
3(h)(1)
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 2,500 | | | | | | (2,500) | | | | | | — | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | |
Total Business Combination adjustments
|
| | | | | | | 50,891,756 | | | | | | 5 | | | | | | 9,839,696 | | | | | | 1 | | | | | | (6,503,073) | | | | | | (1) | | | | | | 274,820 | | | | | | 4,047 | | | | | | 278,872 | | | | | | | (20,700,000) | | | | | | (207,000) | | | | | | (109,182,191) | | | | | | (158,747) | | | | | | (57,500,000) | | | | | | (9,350) | | | | | |
Post-Business Combination equity balance
|
| | | | | | | 51,505,756 | | | | | $ | 5 | | | | | | 15,014,696 | | | | | $ | 2 | | | | | | — | | | | | $ | — | | | | | $ | 283,993 | | | | | $ | (114,438) | | | | | $ | 169,562 | | | | | | | — | | | | | $ | — | | | | | | — | | | | | $ | — | | | | | | — | | | | | $ | — | | | | ||
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Fair value of common stock | | | $9.88 | |
| Expected volatility | | | 53.5% | |
| Risk-free interest rate | | | 0.33% | |
| Expected term | | | 3 years | |
| Expected dividend yield | | | The expected dividend yield is zero as the combined company has never declared or paid cash dividends and has no current plans to do so during the expected term | |
| | |
Nine months ended
September 30, 2021 |
| |
Year ended
December 31, 2020 |
| ||||||
Research and development
|
| | | $ | 401 | | | | | $ | 535 | | |
General and administrative
|
| | | | 1,118 | | | | | | 1,491 | | |
Sales and marketing
|
| | | | 26 | | | | | | 35 | | |
| | | | $ | 1,545 | | | | | $ | 2,061 | | |
| Fair value of common stock | | | $10.00 | |
| Expected volatility | | |
Volatility before SPAC transaction — 12.7%
Volatility after SPAC transaction — 68.9%
|
|
| Risk-free interest rate | | | 1.3% | |
| Expected dividend yield | | | The expected dividend yield is zero as the combined company has never declared or paid cash dividends and has no current plans to do so during the expected term | |
Name
|
| |
Age
|
| |
Position
|
| |||
Arthur Cohen | | | | | 59 | | | |
Chief Executive Officer and Director
|
|
Christine Clarke | | | | | 43 | | | | Chief Financial Officer | |
George Petrocheilos | | | | | 30 | | | | President | |
Joseph Healey | | | | | 55 | | | | Director (Chairman) | |
Benjamin Snedeker | | | | | 46 | | | | Director | |
Dr. Kenan Turnacioglu | | | | | 54 | | | | Director | |
Michael Weinstein | | | | | 51 | | | | Director | |
Dr. Christopher Wolfgang | | | | | 55 | | | | Director | |
Taylor Harris | | | | | 45 | | | | Director | |
Family
Number |
| |
Patent
Protection Type |
| |
Jurisdictions with
Pending Applications |
| |
Jurisdictions with
Granted Patents |
| |
Title
|
|
1 | | | Utility | | | AU, BR, CA (3), CN, EP, HK (2), IL, IN, JP, KR, MX, US (2) | | | AU (2), CN, JP (2), US (3) | | | Low field magnetic resonance imaging methods and apparatus | |
Family
Number |
| |
Patent
Protection Type |
| |
Jurisdictions with
Pending Applications |
| |
Jurisdictions with
Granted Patents |
| |
Title
|
|
2 | | | Utility | | | BR, CA, CN, EP, HK, IL (2), IN, JP, KR, US | | | AU, CA, CN, HK, JP (2), MX, US (5) | | | Noise suppression methods and apparatus | |
3 | | | Utility | | | AU, CA (2), CN, EP, HK (2), KR, US | | | AU, JP (2), US (2) | | | Pulse sequences for low field magnetic resonance | |
4 | | | Utility | | | | | | US | | | Low field magnetic resonance methods and apparatus | |
5 | | | Utility | | | CA, EP | | | US | | | Thermal management methods and apparatus | |
6 | | | Utility | | | BR, CA, EP, HK (2), IL, IN, KR | | | AU, CN, JP, MX, TW, US (5) | | | Magnetic coil power methods and apparatus | |
7 | | | Utility | | | BR, EP, HK (2), IL, IN, KR, US | | | AU, CA, CN, JP, TW, US (2) | | | Radio frequency coil methods and apparatus | |
8 | | | Utility | | | BR, CA, CN, EP, HK, IL, IN, KR, MX, US (2) | | | AU, CN, HK, JP, TW (2), US (6) | | | Automatic configuration of a low field magnetic resonance imaging system | |
9 | | | Utility | | | AU, BR, CA, CN, EP, HK, IL, IN, JP, KR, MX, US | | | TW (2), US (2) | | | Radio frequency coil tuning methods and apparatus | |
10 | | | Utility | | | BR, CN, EP, HK (2), IN, JP, KR, MX, US | | | AU, CA, CN, HK, JP, IL, TW, US (3) | | | Ferromagnetic augmentation for magnetic resonance imaging | |
11 | | | Utility | | | AU, BR, CA, CN, EP, HK, IL, IN, JP, KR, MX, US | | | TW, US (6) | | | Systems and methods for automated detection in magnetic resonance images | |
12 | | | Utility | | | AU, BR, CA (2), EP, IL, IN, KR, MX, US | | | CA, CN, HK, JP, TW (2), US (4) | | | Methods and apparatus for magnetic field shimming | |
13 | | | Utility | | | AU, BR, CA, CN, EP, HK, IL, IN, JP, KR, MX, US | | | TW (2) | | | Portable low-field magnetic resonance imaging methods and apparatus | |
14 | | | Utility | | | US, counterpart foreign cases in 13 family | | | US (5) | | | Electromagnetic shielding for magnetic resonance imaging methods and apparatus | |
15 | | | Utility | | | US, counterpart foreign cases in 13 family | | | US (4) | | | Portable magnetic resonance imaging methods and apparatus | |
16 | | | Utility | | | AU, BR, CA, CN, EP, IL, IN, JP, KR, MX, TW, US (4) | | | US | | | Methods and apparatus for patient positioning in magnetic resonance imaging | |
17 | | | Utility | | | US (1), counterpart foreign cases in 13 family | | | US (12) | | | Low-field magnetic resonance imaging methods and apparatus | |
18 | | | Utility | | | Counterpart foreign cases in 13 family | | | US (5) | | | Rotatable magnet methods and apparatus for a magnetic resonance imaging system | |
19 | | | Utility | | | AU, BR, CA, CN, EP, HK, IL, IN, JP, KR, MX, TW, US (3) | | | US (3) | | | Radio-frequency coil signal chain for a low-field mri system | |
Family
Number |
| |
Patent
Protection Type |
| |
Jurisdictions with
Pending Applications |
| |
Jurisdictions with
Granted Patents |
| |
Title
|
|
20 | | | Utility | | | AU, BR, CA, CN, EP, HK, IL, IN, JP, KR, MX, TW, US | | | US | | | Deployable guard for portable magnetic resonance imaging devices | |
21 | | | Utility | | | AU, BR, CA, CN, EP, HK, IL, IN, JP, KR, MX, TW, US | | | | | | B0 magnet methods and apparatus for a magnetic resonance imaging system | |
22 | | | Utility | | | AU, CA, CN, EP, JP, KR, TW, US (2) | | | | | | Deep learning techniques for magnetic resonance image reconstruction | |
23 | | | Utility | | | AU, CA, CN, EP, HK, JP, KR, TW, US | | | | | | Medical imaging device messaging service | |
24 | | | Utility | | | AU, CA, CN, EP, JP, KR, TW, US | | | US | | | Low-field diffusion weighted imaging | |
25 | | | Utility | | | AU, CA, CN, EP, JP, KR, TW, US | | | | | | Deep learning techniques for suppressing artefacts in magnetic resonance images | |
26 | | | Utility | | | AU, CA, EP, NZ, TW, US | | | US | | | System and methods for grounding patients during magnetic resonance imaging | |
27 | | | Utility | | | AU, BR, CA, EP, IL, IN, JP, KR, MX, NZ, TW, US (2) | | | US | | | Correcting for hysteresis in magnetic resonance imaging | |
28 | | | Utility | | | US, PCT | | | | | | Techniques for dynamic control of a magnetic resonance imaging system | |
29 | | | Utility | | | US (2), PCT | | | | | | System and methods for detecting electromagnetic interference in patients during magnetic resonance imaging | |
30 | | | Utility | | | AU, BR, CA, EP, IL, IN, JP, MX, NZ, TW, US, PCT | | | | | | Systems and methods for magnetic resonance imaging of infants | |
31 | | | Utility | | | US, counterpart foreign cases in 32 family | | | | | | Deep learning techniques for alignment of magnetic resonance images | |
32 | | | Utility | | | AU, BR, CA, EP, IL, IN, JP, MX, NZ, US, PCT | | | | | | Deep learning techniques for generating magnetic resonance images from spatial frequency data | |
33 | | | Utility | | | US | | | | | | Low noise gradient amplification components for mr systems | |
34 | | | Utility | | | US (2), PCT | | | | | | Systems, devices, and methods for magnetic resonance imaging of infants | |
35 | | | Utility | | | US, counterpart foreign cases in 16 family | | | | | | Patient support bridge methods and apparatus | |
36 | | | Utility | | | US (2), PCT | | | | | | Systems and methods for detecting patient motion during magnetic resonance imaging | |
Family
Number |
| |
Patent
Protection Type |
| |
Jurisdictions with
Pending Applications |
| |
Jurisdictions with
Granted Patents |
| |
Title
|
|
37 | | | Utility | | | US, counterpart foreign cases in 32 family | | | | | | Multi-coil magnetic resonance imaging using deep learning | |
38 | | | Utility | | | US, PCT | | | | | | Eddy current mitigation systems and methods | |
39 | | | Utility | | | US (3), PCT | | | | | | Artefact reduction in magnetic resonance imaging | |
40 | | | Utility | | | US (2), PCT | | | | | | Techniques for displaying medical image data | |
41 | | | Utility | | | US, PCT | | | | | | Systems and methods for generating three-dimensional medical images using ray tracing | |
42 | | | Utility | | | US (2), counterpart foreign cases in 32 family | | | | | | Self ensembling techniques for generating magnetic resonance images from spatial frequency data | |
43 | | | Utility | | | TW, US, PCT | | | | | | Magnetic resonance imaging magnet assembly systems and methods | |
44 | | | Utility | | | US (2), PCT | | | | | | Ferromagnetic frame for magnetic resonance imaging | |
45 | | | Utility | | | US (2), PCT | | | | | | Permanent magnet assembly for magnetic resonance imaging with non-ferromagnetic frame | |
46 | | | Utility | | | US, PCT | | | | | | Swaged component magnet assembly for magnetic resonance imaging | |
47 | | | Utility | | | US, PCT | | | | | | Techniques for noise suppression in an environment of a magnetic resonance imaging system | |
48 | | | Design | | | | | | US | | | Frame for magnets in magnetic resonance imaging | |
49 | | | Design | | | | | | US | | | Frame for magnets in magnetic resonance imaging | |
50 | | | Utility | | | US (2), PCT | | | | | | Gradient waveform design for low-field magnetic resonance imaging systems | |
51 | | | Utility | | | US, PCT | | | | | | Systems and methods for low-field fast spin echo imaging | |
52 | | | Utility | | | US, PCT, TW | | | | | | Systems and methods for providing operating power to a magnetic resonance imaging (MRI) system | |
53 | | | Utility | | | US, PCT | | | | | | Deep learning methods for noise suppression in medical imaging | |
54 | | |
Utility (prov)
|
| | US | | | | | | Title not publicly available | |
55 | | |
Utility (prov)
|
| | US | | | | | | Title not publicly available | |
56 | | |
Utility (prov)
|
| | US | | | | | | Title not publicly available | |
57 | | |
Utility (prov)
|
| | US | | | | | | Title not publicly available | |
58 | | |
Utility (prov)
|
| | US | | | | | | Title not publicly available | |
59 | | |
Utility (prov)
|
| | US | | | | | | Title not publicly available | |
60 | | |
Utility (prov)
|
| | US | | | | | | Title not publicly available | |
61 | | |
Utility (prov)
|
| | US | | | | | | Title not publicly available | |
Family
Number |
| |
Patent
Protection Type |
| |
Jurisdictions with
Pending Applications |
| |
Jurisdictions with
Granted Patents |
| |
Title
|
|
62 | | |
Utility (prov)
|
| | US | | | | | | Title not publicly available | |
63 | | |
Utility (prov)
|
| | US | | | | | | Title not publicly available | |
64 | | |
Utility (prov)
|
| | US | | | | | | Title not publicly available | |
65 | | |
Utility (prov)
|
| | US | | | | | | Title not publicly available | |
Family
Number |
| |
Patent
Protection Type |
| |
Jurisdictions with
Pending Applications |
| |
Jurisdictions with
Granted Patents |
| |
Title
|
|
1 | | | Utility | | | AU, BR, CA, CN, EP, IL, IN, JP, KR, MX, TW, US | | | | | | Systems and methods for a wearable device including stimulation and monitoring components | |
2 | | | Utility | | | AU, BR, CA, CN, EP, IL, IN, JP, KR, MX, TW, US | | | | | | Systems and methods for a wearable device for substantially non-destructive acoustic stimulation | |
3 | | | Utility | | | AU, BR, CA, CN, EP, IL, IN, JP, KR, MX, TW, US | | | | | | Systems and methods for a wearable device for acoustic stimulation | |
4 | | | Utility | | | AU, CA, EP, TW, US | | | | | | Systems and methods for a wearable device for treating a health condition using ultrasound stimulation | |
5 | | | Utility | | | AU, BR, CA, CN, EP, IL, IN, JP, KR, MX, TW, US | | | | | | Systems and methods for a device for steering acoustic stimulation using machine learning | |
6 | | | Utility | | | AU, BR, CA, CN, EP, IL, IN, JP, KR, MX, TW, US | | | | | | Systems and methods for a device using a statistical model trained on annotated signal data | |
7 | | | Utility | | | AU, CA, EP, TW, US | | | | | | Systems and methods for a device for energy efficient monitoring of the brain | |
8 | | | Utility | | | TW, US, PCT | | | | | | Systems and methods for monitoring brain health | |
9 | | | Utility | | | TW, US, counterpart foreign cases in 8 family | | | | | | Systems and methods for monitoring brain health | |
10 | | | Utility | | | US, PCT | | | | | | Systems and methods for a brain acoustic resonance intracranial pressure monitor | |
Family
Number |
| |
Patent
Protection Type |
| |
Jurisdictions with
Pending Applications |
| |
Jurisdictions with
Granted Patents |
| |
Title
|
|
11 | | | Utility | | | US, counterpart foreign cases in 10 family | | | | | | Systems and methods for a skull lamb waves intracranial pressure monitor | |
12 | | | Utility | | | US, counterpart foreign cases in 10 family | | | | | | Systems and methods for a brain acoustic resonance seizure monitor | |
13 | | | Utility | | | US, counterpart foreign cases in 10 family | | | | | | Systems and methods for tumor detection | |
14 | | | Utility | | | US, counterpart foreign cases in 10 family | | | | | | Systems and methods for mapping distribution of intracranial pressure | |
15 | | | Utility | | | US, counterpart foreign cases in 10 family | | | | | | Systems and methods for seizure localization | |
16 | | | Utility | | | TW, US, PCT | | | | | | Device and methods for treating neurological disorders and brain conditions | |
17 | | | Utility | | | US, PCT | | | | | | Ultrasound annular array device for neuromodulation | |
18 | | | Utility | | | US, PCT | | | | | | Methods and apparatus for pulsatility-mode sensing | |
19 | | | Utility | | | US, PCT | | | | | | Methods and apparatus for smart beam-steering | |
20 | | |
Utility (prov)
|
| | US | | | | | | Title not publicly available | |
21 | | |
Utility (prov)
|
| | US | | | | | | Title not publicly available | |
22 | | |
Utility (prov)
|
| | US | | | | | | Title not publicly available | |
23 | | |
Utility (prov)
|
| | US | | | | | | Title not publicly available | |
| | |
Nine Months
Ended September 30, |
| |
Change
|
| |
Year Ended December 31,
|
| |
Change
|
| ||||||||||||||||||||||||
(In thousands)
|
| |
2021
|
| |
2020
|
| |
%
|
| |
2020
|
| |
2019
|
| |
%
|
| ||||||||||||||||||
Sales | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Device
|
| | | $ | 521 | | | | | $ | 77 | | | | | | 576.6% | | | | | $ | 200 | | | | | $ | — | | | | | | n/m | | |
Service
|
| | | | 539 | | | | | | 10 | | | | | | 5290.0% | | | | | | 94 | | | | | | — | | | | | | n/m | | |
Total sales
|
| | | $ | 1,060 | | | | | $ | 87 | | | | | | 1118.4% | | | | | $ | 294 | | | | | $ | — | | | | | | n/m | | |
Cost of Sales | | | | | | | | ||||||||||||||||||||||||||||||
Device
|
| | | $ | 1,420 | | | | | $ | 368 | | | | | | 285.9% | | | | | $ | 763 | | | | | $ | — | | | | | | n/m | | |
Service
|
| | | | 354 | | | | | | | | | | | | n/m | | | | | | 8 | | | | | | — | | | | | | n/m | | |
Cost of sales
|
| | | $ | 1,774 | | | | | $ | 368 | | | | | | 382.1% | | | | | $ | 771 | | | | | $ | — | | | | | | n/m | | |
Gross margin
|
| | | | (714) | | | | | | (281) | | | | | | 154.1% | | | | | | (477) | | | | | | — | | | | | | n/m | | |
Operating expenses: | | | | | | | | ||||||||||||||||||||||||||||||
Research and development
|
| | | $ | 16,949 | | | | | $ | 11,042 | | | | | | 53.5% | | | | | $ | 14,593 | | | | | $ | 13,390 | | | | | | 9.0% | | |
General and administrative
|
| | | | 15,348 | | | | | | 3,781 | | | | | | 305.9% | | | | | | 5,921 | | | | | | 5,810 | | | | | | 1.9% | | |
Sales and marketing
|
| | | | 5,770 | | | | | | 1,527 | | | | | | 277.9% | | | | | | 2,500 | | | | | | 768 | | | | | | 225.5% | | |
Total operating expenses
|
| | | | 38,067 | | | | | | 16,350 | | | | | | 132.8% | | | | | | 23,014 | | | | | | 19,968 | | | | | | 15.3% | | |
Loss from operations
|
| | | $ | (38,781) | | | | | $ | (16,631) | | | | | | 133.2% | | | | | $ | (23,491) | | | | | $ | (19,968) | | | | | | 17.6% | | |
Interest income
|
| | | $ | 13 | | | | | $ | 66 | | | | | | (80.3%) | | | | | $ | 70 | | | | | $ | 630 | | | | | | (88.9)% | | |
Other income (expense), net
|
| | | | 2 | | | | | | — | | | | | | n/m | | | | | | (6) | | | | | | (77) | | | | | | (92.2)% | | |
Loss before provision for income taxes
|
| | | $ | (38,766) | | | | | $ | (16,565) | | | | | | 134.0% | | | | | $ | (23,427) | | | | | $ | (19,415) | | | | | | 20.7% | | |
Provision for income taxes
|
| | | | — | | | | | | — | | | | | | n/m | | | | | | — | | | | | | — | | | | | | n/m | | |
Net loss and comprehensive loss
|
| | | $ | (38,766) | | | | | $ | (16,565) | | | | | | 134.0% | | | | | $ | (23,427) | | | | | $ | (19,415) | | | | | | 20.7% | | |
| | |
Nine Months Ended September 30,
|
| |
Change
|
| ||||||||||||||||||
| | |
2021
|
| |
2020
|
| |
Amount
|
| |
%
|
| ||||||||||||
Device
|
| | | $ | 521 | | | | | $ | 77 | | | | | $ | 444 | | | | | | 576.6% | | |
Service
|
| | | | 539 | | | | | | 10 | | | | | | 529 | | | | | | 5290.0% | | |
Total sales
|
| | | $ | 1,060 | | | | | $ | 87 | | | | | $ | 973 | | | | | | 1118.4% | | |
| | |
Nine Months Ended September 30,
|
| |
Change
|
| ||||||||||||||||||
| | |
2021
|
| |
2020
|
| |
Amount
|
| |
%
|
| ||||||||||||
Device
|
| | | $ | 1,420 | | | | | $ | 368 | | | | | $ | 1,052 | | | | | | 285.9% | | |
Service
|
| | | | 354 | | | | | | — | | | | | $ | 354 | | | | | | n/m | | |
Total cost of sales
|
| | | $ | 1,774 | | | | | $ | 368 | | | | | $ | 1,406 | | | | | | 382.1% | | |
| | |
Nine Months Ended September 30,
|
| |
Change
|
| ||||||||||||||||||
| | |
2021
|
| |
2020
|
| |
Amount
|
| |
%
|
| ||||||||||||
Research and development
|
| | | $ | 16,949 | | | | | $ | 11,042 | | | | | $ | 5,907 | | | | | | 53.5% | | |
| | |
Nine Months Ended September 30,
|
| |
Change
|
| ||||||||||||||||||
| | |
2021
|
| |
2020
|
| |
Amount
|
| |
%
|
| ||||||||||||
General and administrative
|
| | | $ | 15,348 | | | | | $ | 3,781 | | | | | $ | 11,567 | | | | | | 305.9% | | |
| | |
Nine Months Ended September 30,
|
| |
Change
|
| ||||||||||||||||||
| | |
2021
|
| |
2020
|
| |
Amount
|
| |
%
|
| ||||||||||||
Sales and marketing
|
| | | $ | 5,770 | | | | | $ | 1,527 | | | | | $ | 4,243 | | | | | | 277.9% | | |
| | |
Nine Months Ended September 30,
|
| |
Change
|
| ||||||||||||||||||
| | |
2021
|
| |
2020
|
| |
Amount
|
| |
%
|
| ||||||||||||
Interest income
|
| | | $ | 13 | | | | | $ | 66 | | | | | $ | (53) | | | | | | (80.3)% | | |
| | |
Nine Months Ended September 30,
|
| |
Change
|
| ||||||||||||||||||
| | |
2021
|
| |
2020
|
| |
Amount
|
| |
%
|
| ||||||||||||
Other income (expense), net
|
| | | $ | 2 | | | | | $ | — | | | | | $ | 2 | | | | | | n/m | | |
| | |
Year Ended December 31,
|
| |
Change
|
| ||||||||||||||||||
|
2020
|
| |
2019
|
| |
Amount
|
| |
%
|
| ||||||||||||||
Device
|
| | | $ | 200 | | | | | $ | — | | | | | $ | 200 | | | | | | n/m | | |
Service
|
| | | | 94 | | | | | | — | | | | | | 94 | | | | | | n/m | | |
Total sales
|
| | | $ | 294 | | | | | $ | — | | | | | $ | 294 | | | | | | n/m | | |
| | |
Year Ended December 31,
|
| |
Change
|
| ||||||||||||||||||
|
2020
|
| |
2019
|
| |
Amount
|
| |
%
|
| ||||||||||||||
Device
|
| | | $ | 763 | | | | | $ | — | | | | | $ | 763 | | | | | | n/m | | |
| | |
Year Ended December 31,
|
| |
Change
|
| ||||||||||||||||||
|
2020
|
| |
2019
|
| |
Amount
|
| |
%
|
| ||||||||||||||
Service
|
| | | | 8 | | | | | | — | | | | | | 8 | | | | | | n/m | | |
Total cost of sales
|
| | | $ | 771 | | | | | $ | — | | | | | $ | 771 | | | | | | n/m | | |
| | |
Year Ended December 31,
|
| |
Change
|
| ||||||||||||||||||
|
2020
|
| |
2019
|
| |
Amount
|
| |
%
|
| ||||||||||||||
Research and development
|
| | | $ | 14,593 | | | | | $ | 13,390 | | | | | $ | 1,203 | | | | | | 9.0% | | |
| | |
Year Ended December 31,
|
| |
Change
|
| ||||||||||||||||||
|
2020
|
| |
2019
|
| |
Amount
|
| |
%
|
| ||||||||||||||
General and administrative
|
| | | $ | 5,921 | | | | | $ | 5,810 | | | | | $ | 111 | | | | | | 1.9% | | |
| | |
Year Ended December 31,
|
| |
Change
|
| ||||||||||||||||||
|
2020
|
| |
2019
|
| |
Amount
|
| |
%
|
| ||||||||||||||
Sales and marketing
|
| | | $ | 2,500 | | | | | $ | 768 | | | | | $ | 1,732 | | | | | | 225.5% | | |
| | |
Year Ended December 31,
|
| |
Change
|
| ||||||||||||||||||
|
2020
|
| |
2019
|
| |
Amount
|
| |
%
|
| ||||||||||||||
Interest income
|
| | | $ | 70 | | | | | $ | 630 | | | | | $ | (560) | | | | | | (88.9)% | | |
| | |
Year Ended December 31,
|
| |
Change
|
| ||||||||||||||||||
|
2020
|
| |
2019
|
| |
Amount
|
| |
%
|
| ||||||||||||||
Other income (expense), net
|
| | | $ | (6) | | | | | $ | (77) | | | | | $ | 71 | | | | | | (92.2)% | | |
| | |
Nine Months Ended September 30,
|
| |
Year Ended December 31,
|
| ||||||||||||||||||
| | |
2021
|
| |
2020
|
| |
2020
|
| |
2019
|
| ||||||||||||
Net cash used in operating activities
|
| | | $ | (29,047) | | | | | $ | (13,711) | | | | | $ | (21,525) | | | | | $ | (18,372) | | |
Net cash used in investing activities
|
| | | $ | (1,736) | | | | | $ | (795) | | | | | $ | (1,568) | | | | | $ | (244) | | |
Net cash provided by financing activities
|
| | | $ | 35,439 | | | | | $ | 1,631 | | | | | $ | 60,938 | | | | | $ | 4,736 | | |
Net increase (decrease) in cash, cash equivalents, and restricted cash
|
| | | $ | 4,656 | | | | | $ | (12,875) | | | | | $ | 37,845 | | | | | $ | (13,880) | | |
Name and Position
|
| |
Year
|
| |
Salary ($)
|
| |
Bonus
($) |
| |
Stock
Awards ($) |
| |
Option
Awards ($)(1) |
| |
All Other
Compensation ($) |
| |
Total ($)
|
| |||||||||||||||||||||
Mark Hughes,
Chief Operating Officer |
| | | | 2020 | | | | | $ | 225,000(2) | | | | | $ | 100,000 | | | | | $ | — | | | | | $ | 120,878(3) | | | | | $ | — | | | | | $ | 445,878 | | |
Khan Siddiqui, M.D.,
Chief Medical Officer and Chief Strategy Officer(4) |
| | | | 2020 | | | | | $ | 255,208 | | | | | $ | 150,000 | | | | | $ | — | | | | | $ | 494,241(5) | | | | | $ | — | | | | | $ | 899,449 | | |
| | |
Option Awards
|
| |
Stock Awards
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Name
|
| |
Grant
Date |
| |
Number of
Securities Underlying Unexercised Options Exercisable (#) |
| |
Number of
Securities Underlying Unexercised Options Unexercisable (#) |
| |
Equity
Incentive Plan Awards: Number of Securities Underlying Unexercised Unearned Options (#) |
| |
Option
Exercise Price |
| |
Option
Expiration Date |
| |
Number
of Shares or Units That have Not Vested |
| |
Market
Value of Shares or Units of Stock That Have Not Vested |
| |
Equity
Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights That Have Not Vested |
| |
Equity
Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units Or Other Rights That Have Not Vested |
| ||||||||||||||||||||||||||||||
Mark Hughes
|
| | | | 7/1/2019 | | | | | | 39,062(1) | | | | | | 85,938 | | | | | | — | | | | | $ | 1.23 | | | | | | 7/1/2029 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | | | 1/18/2020 | | | | | | 41,250(2) | | | | | | 123,750 | | | | | | — | | | | | $ | 1.23 | | | | | | 1/18/2030 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | | | 1/18/2020 | | | | | | 2,500(3) | | | | | | 7,500 | | | | | | — | | | | | $ | 1.23 | | | | | | 1/18/2030 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Khan Siddiqui, M.D.
|
| | | | 1/27/2020 | | | | | | 80,000(4) | | | | | | 240,000 | | | | | | — | | | | | $ | 1.23 | | | | | | 1/27/2030 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | | | 1/27/2020 | | | | | | 99,500(5) | | | | | | 298,500 | | | | | | | | | | | $ | 1.23 | | | | | | 1/27/2030 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Name
|
| |
Age
|
| |
Position
|
|
Executive Officers: | | | | | | | |
Dave Scott | | |
50
|
| | Chief Executive Officer and Director | |
Alok Gupta | | |
56
|
| | Chief Financial Officer | |
Mark Hughes | | |
58
|
| | Chief Operating Officer | |
Khan Siddiqui, M.D. | | |
48
|
| | Chief Medical Officer and Chief Strategy Officer | |
Neela Paykel | | |
52
|
| | General Counsel and Corporate Secretary | |
Scott White | | |
48
|
| | Chief Commercial Officer | |
Non-Employee Directors: | | | | | | | |
Jonathan M. Rothberg, Ph.D. | | |
58
|
| | Director | |
R. Scott Huennekens | | |
57
|
| | Executive Chairman | |
John Dahldorf | | |
65
|
| | Director | |
Ruth Fattori | | |
69
|
| | Director | |
Maria Sainz | | |
56
|
| | Director | |
Daniel J. Wolterman | | |
65
|
| | Director | |
| | |
Before the Business
Combination |
| |
After the Business Combination
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | | | | | | | | | | | | | | | | | |
Assuming No
Redemption |
| | | | | | | |
Assuming
Maximum Redemption |
| | |||||||||||||||||||||||||||||||||||||||||||||||
Name and Address of
Beneficial Owner(1) |
| |
Number of
shares of HealthCor ordinary shares(2) |
| |
%
|
| |
% of
Total Voting Power |
| |
Number of
shares of New Hyperfine Class A Common Stock |
| |
%
|
| |
Number of
shares of New Hyperfine Class B Common Stock |
| |
%
|
| |
% of
Total Voting Power |
| |
Number of
shares of New Hyperfine Class A Common Stock |
| |
%
|
| |
Number of
shares of New Hyperfine Class B Common Stock |
| |
%
|
| |
% of
Total Voting Power |
| |||||||||||||||||||||||||||||||||||||||
HC Sponsor LLC(3)
|
| | | | 5,684,000 | | | | | | 21.5% | | | | | | 21.5% | | | | | | 5,684,000 | | | | | | 7.9% | | | | | | — | | | | | | — | | | | | | 1.5% | | | | | | 5,684,000 | | | | | | 11.0% | | | | | | — | | | | | | — | | | | | | 1.6% | | |
Arthur Cohen
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Christine Clarke
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
George Petrocheilos
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Joseph Healey(3)
|
| | | | 5,684,000 | | | | | | 21.5% | | | | | | 21.5% | | | | | | 5,684,000 | | | | | | 7.9% | | | | | | — | | | | | | — | | | | | | 1.5% | | | | | | 5,684,000 | | | | | | 11.0% | | | | | | — | | | | | | — | | | | | | 1.6% | | |
Benjamin Snedeker
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Dr. Kenan Turnacioglu
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Michael Weinstein
|
| | | | 35,000 | | | | | | * | | | | | | * | | | | | | 35,000 | | | | | | * | | | | | | — | | | | | | — | | | | | | * | | | | | | 35,000 | | | | | | * | | | | | | — | | | | | | — | | | | | | * | | |
Dr. Christopher Wolfgang
|
| | | | 35,000 | | | | | | * | | | | | | * | | | | | | 35,000 | | | | | | * | | | | | | — | | | | | | — | | | | | | * | | | | | | 35,000 | | | | | | * | | | | | | — | | | | | | — | | | | | | * | | |
Taylor Harris
|
| | | | 35,000 | | | | | | * | | | | | | * | | | | | | 35,000 | | | | | | * | | | | | | — | | | | | | — | | | | | | * | | | | | | 35,000 | | | | | | * | | | | | | — | | | | | | — | | | | | | * | | |
Directors and Executive Officers
of HealthCor as a Group (9 Individuals) |
| | |
|
5,789,000
|
| | | |
|
21.9%
|
| | | |
|
21.9%
|
| | | |
|
5,789,000
|
| | | |
|
8.0%
|
| | | | | * | | | | | | — | | | | |
|
1.5%
|
| | | |
|
5,789,000
|
| | | |
|
11.1%
|
| | | | | — | | | | | | — | | | | |
|
1.6%
|
| |
| | |
Before the Business
Combination |
| |
After the Business Combination
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | | | | | | | | | | | | | | | | | |
Assuming No
Redemption |
| | | | | | | |
Assuming
Maximum Redemption |
| | |||||||||||||||||||||||||||||||||||||||||||||||
Name and Address of
Beneficial Owner(1) |
| |
Number of
shares of HealthCor ordinary shares(2) |
| |
%
|
| |
% of
Total Voting Power |
| |
Number of
shares of New Hyperfine Class A Common Stock |
| |
%
|
| |
Number of
shares of New Hyperfine Class B Common Stock |
| |
%
|
| |
% of
Total Voting Power |
| |
Number of
shares of New Hyperfine Class A Common Stock |
| |
%
|
| |
Number of
shares of New Hyperfine Class B Common Stock |
| |
%
|
| |
% of
Total Voting Power |
| |||||||||||||||||||||||||||||||||||||||
Directors and Executive Officers
of New Hyperfine After Consummation of the Business Combination |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Jonathan M. Rothberg, Ph.D.(4)(5)
|
| | | | — | | | | | | — | | | | | | — | | | | | | 2,202,802 | | | | | | 3.0% | | | | | | 15,014,696 | | | | | | 100% | | | | | | 80.9% | | | | | | 2,202,802 | | | | | | 4.2% | | | | | | 15,014,696 | | | | | | 100% | | | | | | 85.7% | | |
Dave Scott(4)
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Alok Gupta(4)
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Mark Hughes(4)(6)
|
| | | | — | | | | | | — | | | | | | — | | | | | | 68,649 | | | | | | * | | | | | | — | | | | | | — | | | | | | * | | | | | | 68,649 | | | | | | * | | | | | | — | | | | | | — | | | | | | * | | |
Khan Siddiqui, M.D.(4)(7)
|
| | | | — | | | | | | — | | | | | | — | | | | | | 125,417 | | | | | | * | | | | | | — | | | | | | — | | | | | | * | | | | | | 125.417 | | | | | | * | | | | | | — | | | | | | — | | | | | | * | | |
Neela Paykel(4)
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Scott White(4)
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | |||||||||||||||
R. Scott Huennekens(4)
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
John Dahldorf(4)
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Ruth Fattori(4)(8)
|
| | | | — | | | | | | — | | | | | | — | | | | | | 886 | | | | | | * | | | | | | — | | | | | | — | | | | | | * | | | | | | 886 | | | | | | * | | | | | | — | | | | | | — | | | | | | * | | |
Maria Sainz(4)
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Daniel J. Wolterman(4)
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
All Directors and Executive
Officers of New Hyperfine as a Group (12 Individuals) |
| | | | — | | | | | | — | | | | | | — | | | | | | 2,397,754 | | | | | | 3.3% | | | | | | 15,014,696 | | | | | | 100% | | | | | | 81.0% | | | | | | 2,397,754 | | | | | | 4.6% | | | | | | 15,014,696 | | | | | | 100% | | | | | | 85.7% | | |
Five Percent Holders: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Jonathan M. Rothberg, Ph.D.(4)(5)
|
| | | | — | | | | | | — | | | | | | — | | | | | | 2,202,802 | | | | | | 3.0% | | | | | | 15,014,696 | | | | | | 100% | | | | | | 80.9% | | | | | | 2,202,802 | | | | | | 4.2% | | | | | | 15,014,696 | | | | | | 100% | | | | | | 85.7% | | |
HC Sponsor LLC(3)
|
| | | | 5,684,000 | | | | | | 21.5% | | | | | | 21.5% | | | | | | 5,684,000 | | | | | | 7.9% | | | | | | — | | | | | | — | | | | | | 1.5% | | | | | | 5,684,000 | | | | | | 11.0% | | | | | | — | | | | | | — | | | | | | 1.6% | | |
| | |
Page(s)
|
| |||
Financial Statements as of December 31, 2020 and for the Period from November 19, 2020 (Inception) through December 31, 2020
|
| | | | | | |
| | | | F-2 | | | |
| | | | F-3 | | | |
| | | | F-4 | | | |
| | | | F-5 | | | |
| | | | F-6 | | | |
| | | | F-7 | | |
| | |
Page(s)
|
| |||
Financial Statements as of September 30, 2021 and December 31, 2020 and for the Three and Nine Months Ended September 30, 2021
|
| | | | | | |
| | | | F-15 | | | |
| | | | F-16 | | | |
| | | | F-17 | | | |
| | | | F-18 | | | |
| | | | F-19 | | |
| | |
Page(s)
|
| |||
Combined Financial Statements as of and for the Years Ended December 31, 2020 and 2019 | | | | | | | |
| | | | F-35 | | | |
| | | | F-36 | | | |
| | | | F-37 | | | |
| | | | F-38 | | | |
| | | | F-39 | | | |
| | | | F-40 | | |
| | |
Page(s)
|
| |||
Condensed Consolidated and Combined Financial Statements (Unaudited) | | | |||||
| | | | F-65 | | | |
| | | | F-66 | | | |
| | | | F-67 | | | |
| | | | F-68 | | | |
| | | | F-69 | | |
| ASSETS | | | | | | | |
|
Deferred offering costs
|
| | | $ | 304,412 | | |
|
TOTAL ASSETS
|
| | | $ | 304,412 | | |
| LIABILITIES AND SHAREHOLDER’S EQUITY | | | | | | | |
| Current liabilities | | | | | | | |
|
Accrued offering costs
|
| | | | 246,037 | | |
|
Promissory note – related party
|
| | | | 38,375 | | |
|
Total Current Liabilities
|
| | | | 284,412 | | |
| Commitments and Contingencies | | | | | | | |
| Shareholder’s Equity | | | | | | | |
|
Preference shares, $0.0001 par value; 5,000,000 shares authorized; no shares issued and outstanding
|
| | | | — | | |
|
Class A ordinary shares, $0.0001 par value; 500,000,000 shares authorized; no shares issued and
outstanding |
| | | | — | | |
|
Class B ordinary shares, $0.0001 par value; 50,000,000 shares authorized; 5,175,000 shares issued and outstanding(1)
|
| | | | 518 | | |
|
Additional paid-in capital
|
| | | | 24,482 | | |
|
Accumulated deficit
|
| | | | (5,000) | | |
|
Total Shareholder’s Equity
|
| | | | 20,000 | | |
|
TOTAL LIABILITIES AND SHAREHOLDER’S EQUITY
|
| | | $ | 304,412 | | |
|
Formation and operating costs
|
| | | $ | 5,000 | | |
|
Net Loss
|
| | | $ | (5,000) | | |
|
Weighted average shares outstanding, basic and diluted(1)
|
| | | | 4,500,000 | | |
|
Basic and diluted net loss per ordinary shares
|
| | | $ | (0.00) | | |
| | |
Class B
Ordinary Shares |
| |
Additional
Paid-in Capital |
| |
Accumulated
Deficit |
| |
Total
Shareholders’ Equity |
| ||||||||||||||||||
| | |
Shares
|
| |
Amount
|
| ||||||||||||||||||||||||
Balance – November 18, 2020 (inception)
|
| | | | — | | | | | $ | — | | | | | $ | — | | | | | $ | — | | | | | $ | — | | |
Issuance of Class B ordinary shares to Sponsor(1)
|
| | | | 5,175,000 | | | | | | 518 | | | | | | 24,482 | | | | | | — | | | | | | 25,000 | | |
Net loss
|
| | | | — | | | | | | — | | | | | | — | | | | | | (5,000) | | | | | | (5,000) | | |
Balance – December 31, 2020
|
| | | | 5,175,000 | | | | | $ | 518 | | | | | $ | 24,482 | | | | | $ | (5,000) | | | | | $ | 20,000 | | |
| Cash Flows from Operating Activities: | | | | | | | |
|
Net loss
|
| | | $ | (5,000) | | |
|
Adjustments to reconcile net loss to net cash used in operating activities:
|
| | | | | | |
|
Payment of formation costs through issuance of Class B ordinary shares
|
| | | | 5,000 | | |
|
Net cash used in operating activities
|
| | | | — | | |
| Cash Flows from Financing Activities: | | | | | | | |
|
Proceeds from promissory note – related party
|
| | | | 38,375 | | |
|
Payment of offering costs
|
| | | | (38,375) | | |
|
Net cash provided by (used in) financing activities
|
| | | | — | | |
|
Net Change in Cash
|
| | | | — | | |
|
Cash – Beginning
|
| | | | — | | |
| Cash – Ending | | | |
$
|
—
|
| |
| Non-cash investing and financing activities: | | | | | | | |
|
Offering costs included in accrued offering costs
|
| | | $ | 246,037 | | |
|
Deferred offering costs paid by Sponsor in exchange for the issuance of common stock
|
| | | $ | 20,000 | | |
| | |
September 30, 2021
|
| |
December 31, 2020
|
| ||||||
| | |
(Unaudited)
|
| | | | | | | |||
ASSETS | | | | | | | | | | | | | |
Current assets | | | | | | | | | | | | | |
Cash
|
| | | $ | 525,404 | | | | | $ | — | | |
Prepaid expenses
|
| | | | 402,195 | | | | | | — | | |
Total Current Assets
|
| | | | 927,599 | | | | | | — | | |
Deferred offering costs
|
| | | | — | | | | | | 304,412 | | |
Marketable securities held in Trust Account
|
| | | | 207,014,497 | | | | | | — | | |
TOTAL ASSETS
|
| | | $ | 207,942,096 | | | | | $ | 304,412 | | |
LIABILITIES AND SHAREHOLDERS’ (DEFICIT)EQUITY | | | | | | | | | | | | | |
Current liabilities | | | | | | | | | | | | | |
Accounts payable and accrued expenses
|
| | | $ | 1,938,902 | | | | | $ | — | | |
Accrued offering costs
|
| | | | 7,515 | | | | | | 246,037 | | |
Promissory note – related party
|
| | | | — | | | | | | 38,375 | | |
Total Current Liabilities
|
| | | | 1,946,417 | | | | | | 284,412 | | |
Deferred underwriting fee payable
|
| | | | 7,245,000 | | | | | | — | | |
TOTAL LIABILITIES
|
| | | | 9,191,417 | | | | | | 284,412 | | |
Commitments and Contingencies | | | | | | | | | | | | | |
Class A ordinary shares subject to possible redemption 20,700,000 and no shares at redemption value of $10.00 as of September 30, 2021 and December 31, 2020, respectively
|
| | | | 207,000,000 | | | | | | — | | |
Shareholders’ (Deficit) Equity | | | | | | | | | | | | | |
Preference shares, $0.0001 par value; 5,000,000 shares authorized; no shares issued and outstanding
|
| | | | — | | | | | | — | | |
Class A ordinary shares, $0.0001 par value; 500,000,000 shares
authorized; 614,000 and no shares issued and outstanding as of September 30, 2021 and December 31, 2020, (excluding 20,700,000 shares subject to possible redemption at September 30, 2021 and no shares at December 31, 2020) respectively |
| | | | 61 | | | | | | — | | |
Class B ordinary shares, $0.0001 par value; 50,000,000 shares authorized; 5,175,000 shares issued and outstanding, at September 30, 2021 and December 31, 2020
|
| | | | 518 | | | | | | 518 | | |
Additional paid-in capital
|
| | | | — | | | | | | 24,482 | | |
Accumulated deficit
|
| | | | (8,249,900) | | | | | | (5,000) | | |
Total Shareholders’ (Deficit) Equity
|
| | | | (8,249,321) | | | | | | 20,000 | | |
TOTAL LIABILITIES AND SHAREHOLDERS’ (DEFICIT) EQUITY
|
| | | $ | 207,942,096 | | | | | $ | 304,412 | | |
| | |
Three Months Ended
September 30, 2021 |
| |
Nine Months Ended
September 30, 2021 |
| ||||||
Operating and formation costs
|
| | | $ | 900,417 | | | | | $ | 2,494,910 | | |
Loss from operations
|
| | | | (900,417) | | | | | | (2,494,910) | | |
Other income: | | | | | | | | | | | | | |
Interest earned on marketable securities held in Trust Account
|
| | | | 2,664 | | | | | | 14,497 | | |
Total other income
|
| | | | 2,664 | | | | | | 14,497 | | |
Net loss
|
| | | $ | (897,753) | | | | | $ | (2,480,413) | | |
Weighted average shares outstanding of Class A ordinary shares subject to possible redemption
|
| | | | 20,700,000 | | | | | | 18,501,099 | | |
Basic and diluted net (loss) per share, Class A ordinary shares subject to possible redemption
|
| | | $ | (0.03) | | | | | $ | (0.10) | | |
Weighted average shares outstanding of Class A ordinary shares not subject to possible redemption
|
| | | | 614,000 | | | | | | 548,777 | | |
Basic and diluted net (loss) per share, Class A ordinary shares not subject to possible redemption
|
| | | $ | (0.03) | | | | | $ | (0.10) | | |
Weighted average shares outstanding of Class B ordinary shares not subject to possible redemption
|
| | | | 5,175,000 | | | | | | 5,103,297 | | |
Basic and diluted net (loss) per share, Class B ordinary not shares subject to possible redemption
|
| | | $ | (0.03) | | | | | $ | (0.10) | | |
| | |
Class A
Ordinary Shares |
| |
Class B
Ordinary share |
| |
Additional
Paid-in Capital |
| |
Accumulated
Deficit |
| |
Total
Shareholders’ Equity (Deficit) |
| |||||||||||||||||||||||||||
| | |
Shares
|
| |
Amount
|
| |
Shares
|
| |
Amount
|
| ||||||||||||||||||||||||||||||
Balance – December 31, 2020
|
| | | | — | | | | | $ | — | | | | | | 5,175,000 | | | | | $ | 518 | | | | | $ | 24,482 | | | | | $ | (5,000) | | | | | $ | 20,000 | | |
Sale of 614,000 Private Placement Shares, Net
|
| | | | 614,000 | | | | | | 61 | | | | | | — | | | | | | — | | | | | | 6,139,939 | | | | | | — | | | | | | 6,140,000 | | |
Remeasurement adjustment
for Class A ordinary shares subject to redemption amount |
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (6,164,421) | | | | | | (5,764,487) | | | | | | (11,928,908) | | |
Net loss
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (148,766) | | | | | | (148,766) | | |
Balance – March 31, 2021(1)
|
| | | | 614,000 | | | | | $ | 61 | | | | | | 5,175,000 | | | | | $ | 518 | | | | | $ | — | | | | | $ | (5,918,253) | | | | | $ | (5,917,674) | | |
Net loss
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (1,433,894) | | | | | | (1,433,894) | | |
Balance – June 30, 2021(1)
|
| | | | 614,000 | | | | | $ | 61 | | | | | | 5,175,000 | | | | | $ | 518 | | | | | $ | — | | | | | $ | (7,352,147) | | | | | $ | (7,351,568) | | |
Net loss
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (897,753) | | | | | | (897,753) | | |
Balance – September 30, 2021
|
| | | | 614,000 | | | | | $ | 61 | | | | | | 5,175,000 | | | | | $ | 518 | | | | | $ | — | | | | | $ | (8,249,900) | | | | | $ | (8,249,321) | | |
| Cash Flows from Operating Activities: | | | | | | | |
|
Net loss
|
| | | $ | (2,480,413) | | |
| Adjustments to reconcile net loss to net cash used in operating activities: | | | | | | | |
|
Interest earned on marketable securities held in Trust Account
|
| | | | (14,497) | | |
|
Changes in operating assets and liabilities:
|
| | | | | | |
|
Prepaid expenses
|
| | | | (402,195) | | |
|
Accrued expenses
|
| | | | 1,938,902 | | |
|
Net cash used in operating activities
|
| | | | (958,203) | | |
| Cash Flows from Investing Activities: | | | | | | | |
|
Investment of cash in Trust Account
|
| | | | (207,000,000) | | |
|
Net cash used in investing activities
|
| | | | (207,000,000) | | |
| Cash Flows from Financing Activities: | | | | | | | |
|
Proceeds from sale of Public Shares, net of underwriting discounts paid
|
| | | | 202,860,000 | | |
|
Proceeds from sale of Private Placement Shares
|
| | | | 6,140,000 | | |
|
Proceeds from convertible promissory note – related party
|
| | | | 32,759 | | |
|
Repayment of promissory note – related party, net of related offering costs
|
| | | | (12,760) | | |
|
Repayment of promissory note – related party, related to offering costs
|
| | | | (58,374) | | |
|
Payment of offering costs
|
| | | | (478,018) | | |
|
Net cash provided by financing activities
|
| | | | 208,483,607 | | |
|
Net Change in Cash
|
| | | | 525,404 | | |
|
Cash – Beginning of period
|
| | | | — | | |
|
Cash – End of period
|
| | | $ | 525,404 | | |
| Non-Cash investing and financing activities: | | | | | | | |
|
Offering costs included in accrued offering costs
|
| | | $ | 7,515 | | |
|
Remeasurement adjustment to redemption value
|
| | | $ | 11,928,908 | | |
|
Deferred underwriting fee payable
|
| | | $ | 7,245,000 | | |
Balance Sheet as of January 29, 2021 (Audited)
|
| |
As Previously
Reported |
| |
Adjustment
|
| |
Restated
|
| |||||||||
Class A ordinary shares subject to possible redemption
|
| | | $ | 196,231,090 | | | | | $ | 10,768,910 | | | | | $ | 207,000,000 | | |
Class A ordinary shares
|
| | | $ | 169 | | | | | $ | (108) | | | | | $ | 61 | | |
Additional paid-in capital
|
| | | $ | 5,004,316 | | | | | $ | (5,004,316) | | | | | $ | — | | |
Accumulated deficit
|
| | | $ | (5,000) | | | | | $ | (5,764,486) | | | | | $ | (5,769,486) | | |
Total Shareholders’ Equity (Deficit)
|
| | | $ | 5,000,003 | | | | | $ | (10,768,910) | | | | | $ | (5,768,907) | | |
Balance Sheet as of March 31, 2021 (Unaudited) | | | | | | | | | | | | | | | | | | | |
Class A ordinary shares subject to possible redemption
|
| | | $ | 196,082,323 | | | | | $ | 10,917,677 | | | | | $ | 207,000,000 | | |
Class A ordinary shares
|
| | | $ | 170 | | | | | $ | (109) | | | | | $ | 61 | | |
Additional paid-in capital
|
| | | $ | 5,153,081 | | | | | $ | (5,153,081) | | | | | $ | — | | |
Accumulated deficit
|
| | | $ | (153,766) | | | | | $ | (5,764,487) | | | | | $ | (5,918,253) | | |
Total Shareholders’ Equity (Deficit)
|
| | | $ | 5,000,003 | | | | | $ | (10,917,677) | | | | | $ | (5,917,674) | | |
Balance Sheet as of June 30, 2021 (Unaudited) | | | | | | | | | | | | | | | | | | | |
Class A ordinary shares subject to possible redemption
|
| | | $ | 194,648,426 | | | | | $ | 12,351,574 | | | | | $ | 207,000,000 | | |
Class A ordinary shares
|
| | | $ | 185 | | | | | $ | (124) | | | | | $ | 61 | | |
Additional paid-in capital
|
| | | $ | 6,586,963 | | | | | $ | (6,586,963) | | | | | $ | — | | |
Accumulated deficit
|
| | | $ | (1,587,660) | | | | | $ | (5,764,487) | | | | | $ | (7,352,147) | | |
Total Shareholders’ Equity (Deficit)
|
| | | $ | 5,000,006 | | | | | $ | (12,351,574) | | | | | $ | (7,351,568) | | |
Condensed Statement of Changes in Shareholders’ Equity (Deficit) for the Three Months Ended March 31, 2021 (Unaudited)
|
| | | | | | | | | | | | | | | | | | |
Sale of 20,700,000 Public Shares, net of underwriter discounts and offering expenses
|
| | | $ | 195,071,092 | | | | | $ | (195,071,092) | | | | | $ | — | | |
Sale of 614,000 Private Placement Shares
|
| | | $ | 6,140,000 | | | | | $ | — | | | | | $ | 6,140,000 | | |
Initial value of ordinary shares subject to redemption
|
| | | $ | (196,082,323) | | | | | $ | 196,082,323 | | | | | $ | — | | |
Remeasurement adjustment for Class A ordinary shares to redemption amount
|
| | | $ | — | | | | | $ | (11,928,908) | | | | | $ | (11,928,908) | | |
Total Shareholders’ Equity (Deficit)
|
| | | $ | 5,000,003 | | | | | $ | (10,917,677) | | | | | $ | (5,917,674) | | |
Condensed Statement of Changes in Shareholders’ Equity (Deficit) for the Three Months Ended June 30, 2021 (Unaudited)
|
| | | | | | | | | | | | | | | | | | |
Change in value of ordinary shares subject to
redemption |
| | | $ | 1,433,897 | | | | | $ | (1,433,897) | | | | | $ | — | | |
Total Shareholders’ Equity (Deficit)
|
| | | $ | 5,000,006 | | | | | $ | (12,351,574) | | | | | $ | (7,351,568) | | |
Statement of Cash Flows for the Three Months Ended March 31, 2021 (Unaudited) — Noncash Transaction
|
| | | | | | | | | | | | | | | | | | |
Remeasurement adjustment to redemption value
|
| | | $ | — | | | | | $ | 11,928,908 | | | | | $ | 11,928,908 | | |
Statement of Cash Flows for the Six Months Ended June 30, 2021 (Unaudited) — Noncash Transaction
|
| | | | | | | | | | | | | | | | | | |
Remeasurement adjustment to redemption value
|
| | | $ | — | | | | | | 11,928,908 | | | | | $ | 11,928,908 | | |
| | |
As Previously
Reported For the Three Months Ended March 31, 2021 |
| |
As
Restated For the Three Months Ended March 31, 2021 |
| |
As Previously
As Previously Reported For the Three Months Ended June 30, 2021 |
| |
As
Restated For the Three Months Ended June 30, 2021 |
| |
As Previously
Reported For the Six Months Ended June 30, 2021 |
| |
As
Restated For the Six Months Ended June 30, 2021 |
| ||||||||||||||||||
Basic and diluted weighted average shares outstanding, Class A ordinary shares subject to possible redemption
|
| | | | 19,623,109 | | | | | | 14,030,000 | | | | | | 19,607,812 | | | | | | 20,700,000 | | | | | | 19,613,951 | | | | | | 17,383,425 | | |
Basic and diluted net loss per ordinary share, Class A ordinary shares subject to possible redemption
|
| | | $ | — | | | | | $ | (0.01) | | | | | $ | — | | | | | $ | (0.05) | | | | | $ | — | | | | | $ | (0.07) | | |
Basic and diluted net loss per ordinary share, Class A ordinary shares not subject to possible redemption
|
| | | | — | | | | | $ | 416,156 | | | | | $ | — | | | | | | 614,000 | | | | | | — | | | | | | 515,624 | | |
Basic and diluted weighted average net loss per ordinary shares outstanding, Class A ordinary shares not subject to possible redemption
|
| | | $ | — | | | | | $ | 0.01 | | | | | $ | — | | | | | $ | (0.05) | | | | | $ | — | | | | | $ | (0.07) | | |
Basic and diluted weighted average shares outstanding, Class B ordinary shares
|
| | | | 6,113,916 | | | | | | 4,957,500 | | | | | | 6,881,188 | | | | | | 5,175,000 | | | | | | 6,494,516 | | | | | | 5,066,851 | | |
Basic and diluted net loss per ordinary share, Class B ordinary shares
|
| | | $ | (0.03) | | | | | $ | (0.01) | | | | | $ | (0.21) | | | | | $ | (0.05) | | | | | $ | (0.25) | | | | | $ | (0.07) | | |
|
Gross Proceeds
|
| | | $ | 207,000,000 | | |
| Less: | | | | | | | |
|
Class A ordinary shares issuance costs
|
| | | | (11,928,908) | | |
| Add: | | | | | | | |
|
Remeasurement adjustment of carrying value to redemption value
|
| | | | 11,928,908 | | |
|
Class A ordinary shares subject to possible redemption
|
| | | $ | 207,000,000 | | |
| | |
Three Months Ended
September 30, 2021 |
| |
Nine Months Ended
September 30, 2021 |
| ||||||||||||||||||||||||||||||
| | |
Class A
Redeemable |
| |
Class A
Nonredeemable |
| |
Class B
|
| |
Class A
Redeemable |
| |
Class A
Nonredeemable |
| |
Class B
|
| ||||||||||||||||||
Basic and diluted net loss per ordinary share
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Numerator: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Allocation of net loss, as adjusted
|
| | | $ | (701,555) | | | | | $ | (20,809) | | | | | $ | (175,389) | | | | | $ | (1,899,973) | | | | | $ | (56,357) | | | | | $ | (524,084) | | |
Denominator: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Basic and diluted weighted
average ordinary shares outstanding |
| | | | 20,700,000 | | | | | | 614,000 | | | | | | 5,175,000 | | | | | | 18,501,099 | | | | | | 548,777 | | | | | | 5,103,297 | | |
Basic and diluted net loss per ordinary share
|
| | | $ | (0.03) | | | | | $ | (0.03) | | | | | $ | (0.03) | | | | | $ | (0.10) | | | | | $ | (0.10) | | | | | $ | (0.10) | | |
| | |
Level
|
| |
September 30,
2021 |
| ||||||
Assets: | | | | | | | | | | | | | |
Marketable securities held in Trust Account
|
| | | | 1 | | | | | $ | 207,014,497 | | |
| | |
December 31,
|
| |||||||||
|
2020
|
| |
2019
|
| ||||||||
ASSETS | | | | | | | | | | | | | |
CURRENT ASSETS: | | | | | | | | | | | | | |
Cash and cash equivalents
|
| | | $ | 62,676 | | | | | $ | 26,441 | | |
Restricted cash
|
| | | | 1,610 | | | | | | — | | |
Accounts receivable
|
| | | | 174 | | | | | | — | | |
Inventory
|
| | | | 1,718 | | | | | | — | | |
Prepaid expenses and other current assets
|
| | | | 691 | | | | | | 837 | | |
Due from related parties
|
| | | | 1,465 | | | | | | 683 | | |
Total current assets
|
| | | $ | 68,334 | | | | | $ | 27,961 | | |
Property and equipment
|
| | | | 1,904 | | | | | | 489 | | |
Other assets – related party
|
| | | | 1,244 | | | | | | 1,470 | | |
Prepaid inventory
|
| | | | — | | | | | | 651 | | |
Net investment in lease
|
| | | | 44 | | | | | | — | | |
Total assets
|
| | | $ | 71,526 | | | | | $ | 30,571 | | |
LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ DEFICIT | | | | | | | | | | | | | |
CURRENT LIABILITIES: | | | | | | | | | | | | | |
Accounts payable
|
| | | $ | 948 | | | | | $ | 1,189 | | |
Deferred grant funding
|
| | | | 1,610 | | | | | | — | | |
Deferred revenue
|
| | | | 158 | | | | | | — | | |
Due to related parties
|
| | | | 136 | | | | | | 109 | | |
Accrued expenses and other current liabilities
|
| | | | 1,264 | | | | | | 491 | | |
Total current liabilities
|
| | | $ | 4,116 | | | | | $ | 1,789 | | |
Long term notes payable
|
| | | | 178 | | | | | | — | | |
Total liabilities
|
| | | $ | 4,294 | | | | | $ | 1,789 | | |
COMMITMENTS AND CONTINGENCIES (NOTE 15) | | | | | | | | | | | | | |
CONVERTIBLE PREFERRED STOCK | | | | | | | | | | | | | |
Hyperfine convertible preferred stock (Series A, B, C and D): $.0001 par value, aggregate liquidation preference of $147,651 and $87,882; 129,788,828 and 67,539,894 shares authorized; 95,010,858 and 67,211,210 shares issued and outstanding at December 31, 2020 and 2019, respectively
|
| | | | 128,286 | | | | | | 68,646 | | |
STOCKHOLDERS’ DEFICIT: | | | | | | | | | | | | | |
Hyperfine Common stock, $.0001 par value; 125,000,000 and 57,000,000 shares authorized; 4,812,083 and 4,605,299 shares issued and outstanding at December 31, 2020 and 2019, respectively
|
| | | | — | | | | | | — | | |
Liminal Common stock, $.001 par value; 5,000 shares authorized; 1,000 shares issued and outstanding
|
| | | | — | | | | | | — | | |
Hyperfine Special-voting common stock, $.0001 par value; 25,000,000 shares authorized; 0 shares issued
and outstanding |
| | | | — | | | | | | — | | |
Additional paid-in capital
|
| | | | 10,415 | | | | | | 8,178 | | |
Accumulated deficit
|
| | | | (71,469) | | | | | | (48,042) | | |
Total stockholders’ deficit
|
| | | $ | (61,054) | | | | | $ | (39,864) | | |
TOTAL LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’
DEFICIT |
| | | $ | 71,526 | | | | | $ | 30,571 | | |
| | |
Year ended December 31,
|
| |||||||||
| | |
2020
|
| |
2019
|
| ||||||
Sales | | | | | | | | | | | | | |
Device
|
| | | $ | 200 | | | | | $ | — | | |
Service
|
| | | | 94 | | | | | | — | | |
Total sales
|
| | | $ | 294 | | | | | $ | — | | |
Cost of sales | | | | | | | | | | | | | |
Device
|
| | | $ | 763 | | | | | $ | — | | |
Service
|
| | | | 8 | | | | | | — | | |
Total cost of sales
|
| | | $ | 771 | | | | | $ | — | | |
Gross margin
|
| | | | (477) | | | | | | — | | |
Operating Expenses: | | | | | | | | | | | | | |
Research and development
|
| | | $ | 14,593 | | | | | $ | 13,390 | | |
General and administrative
|
| | | | 5,921 | | | | | | 5,810 | | |
Sales and marketing
|
| | | | 2,500 | | | | | | 768 | | |
Total operating expenses
|
| | | | 23,014 | | | | | | 19,968 | | |
Loss from operations
|
| | | $ | (23,491) | | | | | $ | (19,968) | | |
Interest income
|
| | | $ | 70 | | | | | $ | 630 | | |
Other income (expense), net
|
| | | | (6) | | | | | | (77) | | |
Loss before provision for income taxes
|
| | | $ | (23,427) | | | | | $ | (19,415) | | |
Provision for income taxes
|
| | | | — | | | | | | — | | |
Net loss and comprehensive loss
|
| | | $ | (23,427) | | | | | $ | (19,415) | | |
Net loss per common share attributable to common stockholders, basic and diluted
|
| | | $ | (5.04) | | | | | $ | (4.33) | | |
Weighted-average shares used to compute net loss per share attributable to common stockholders, basic and diluted
|
| | | | 4,651,127 | | | | | | 4,486,484 | | |
| | |
Hyperfine convertible preferred stock
|
| | |
Hyperfine Common Stock
|
| |
Liminal Common Stock
|
| |
Additional
Paid-in Capital |
| |
Accumulated
Deficit |
| |
Total
Shareholders’ Deficit |
| ||||||||||||||||||||||||||||||||||||
|
Shares
|
| |
Amount
|
| | |
Shares
|
| |
Amount
|
| |
Shares
|
| |
Amount
|
| ||||||||||||||||||||||||||||||||||||||
January 1, 2019
|
| | | | 67,211,210 | | | | | $ | 68,646 | | | | | | | 4,435,136 | | | | | $ | — | | | | | | 1,000 | | | | | $ | — | | | | | $ | 1,546 | | | | | $ | (28,627) | | | | | $ | (27,081) | | |
Net loss
|
| | | | — | | | | | | — | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (19,415) | | | | | | (19,415) | | |
Investment from 4Bionics, LLC
|
| | | | — | | | | | | — | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 5,700 | | | | | | — | | | | | | 5,700 | | |
Exercise of stock options
|
| | | | — | | | | | | — | | | | | | | 170,163 | | | | | | — | | | | | | — | | | | | | — | | | | | | 36 | | | | | | — | | | | | | 36 | | |
Stock-based compensation expense
|
| | | | — | | | | | | — | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 896 | | | | | | — | | | | | | 896 | | |
Balance, December 31, 2019
|
| | | | 67,211,210 | | | | | $ | 68,646 | | | | | | | 4,605,299 | | | | | $ | — | | | | | | 1,000 | | | | | $ | — | | | | | $ | 8,178 | | | | | $ | (48,042) | | | | | $ | (39,864) | | |
Net loss
|
| | | | — | | | | | | — | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (23,427) | | | | | | (23,427) | | |
Issuance of Series D convertible
preferred stock, net of issuance costs |
| | | | 27,799,648 | | | | | | 59,640 | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Investment from 4Bionics, LLC
|
| | | | — | | | | | | — | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 1,000 | | | | | | — | | | | | | 1,000 | | |
Exercise of stock options
|
| | | | — | | | | | | — | | | | | | | 206,784 | | | | | | — | | | | | | — | | | | | | — | | | | | | 120 | | | | | | — | | | | | | 120 | | |
Stock-based compensation expense
|
| | | | — | | | | | | — | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 1,117 | | | | | | — | | | | | | 1,117 | | |
Balance, December 31, 2020
|
| | | | 95,010,858 | | | | | $ | 128,286 | | | | | | | 4,812,083 | | | | | $ | — | | | | | | 1,000 | | | | | $ | — | | | | | $ | 10,415 | | | | | $ | (71,469) | | | | | $ | (61,054) | | |
| | |
Year ended December 31,
|
| |||||||||
|
2020
|
| |
2019
|
| ||||||||
Cash flows from operating activities: | | | | | | | | | | | | | |
Net loss
|
| | | $ | (23,427) | | | | | $ | (19,415) | | |
Adjustments to reconcile net loss to net cash used in operating activities:
|
| | | | | | | | | | | | |
Depreciation and amortization
|
| | | | 289 | | | | | | 141 | | |
Loss on disposal of fixed assets
|
| | | | — | | | | | | 4 | | |
Stock-based compensation expense
|
| | | | 1,117 | | | | | | 896 | | |
Write-down of inventory
|
| | | | 213 | | | | | | — | | |
Sales under sales type leases
|
| | | | (46) | | | | | | — | | |
Payments received on net investment in lease
|
| | | | 2 | | | | | | — | | |
Changes in assets and liabilities:
|
| | | | | | | | | | | | |
Accounts receivable
|
| | | | (174) | | | | | | 309 | | |
Inventory
|
| | | | (1,931) | | | | | | — | | |
Prepaid expenses and other current assets
|
| | | | 146 | | | | | | (366) | | |
Due from related parties
|
| | | | (782) | | | | | | (161) | | |
Other assets – related party
|
| | | | 226 | | | | | | 243 | | |
Prepaid inventory
|
| | | | 651 | | | | | | (651) | | |
Accounts payable
|
| | | | (377) | | | | | | 467 | | |
Deferred grant funding
|
| | | | 1,610 | | | | | | — | | |
Deferred revenue
|
| | | | 158 | | | | | | — | | |
Due to related parties
|
| | | | 27 | | | | | | (177) | | |
Accrued expenses and other current liabilities
|
| | | | 773 | | | | | | 338 | | |
Net cash used in operating activities
|
| | | $ | (21,525) | | | | | $ | (18,372) | | |
Cash flows from investing activities: | | | | | | | | | | | | | |
Purchases of fixed assets
|
| | | | (1,568) | | | | | | (244) | | |
Net cash used in investing activities
|
| | | $ | (1,568) | | | | | $ | (244) | | |
Cash flows from financing activities: | | | | | | | | | | | | | |
Proceeds from exercise of stock options
|
| | | | 120 | | | | | | 36 | | |
Proceeds from issuance of Series D convertible preferred stock
|
| | | | 59,769 | | | | | | — | | |
Stock issuance costs for Series D convertible preferred stock
|
| | | | (129) | | | | | | — | | |
Proceeds from issuance of notes payable
|
| | | | 1,067 | | | | | | 1,000 | | |
Repayment of notes payable
|
| | | | (889) | | | | | | (2,000) | | |
Investment from 4Bionics, LLC
|
| | | | 1,000 | | | | | | 5,700 | | |
Net cash provided by financing activities
|
| | | $ | 60,938 | | | | | $ | 4,736 | | |
Net increase (decrease) in cash, cash equivalents and restricted cash
|
| | | | 37,845 | | | | | | (13,880) | | |
Cash, cash equivalents and restricted cash, beginning of year
|
| | | | 26,441 | | | | | | 40,321 | | |
Cash, cash equivalents and restricted cash, end of year
|
| | | $ | 64,286 | | | | | $ | 26,441 | | |
Reconciliation of cash, cash equivalents, and restricted cash reported in the statement of financial position | | | | | | | | | | | | | |
Cash and cash equivalents
|
| | | $ | 62,676 | | | | | $ | 26,441 | | |
Restricted cash
|
| | | | 1,610 | | | | | | — | | |
Total cash, cash equivalents and restricted cash
|
| | | $ | 64,286 | | | | | $ | 26,441 | | |
Supplemental disclosure of cash flow information: | | | | | | | | | | | | | |
Cash received from exchange of research and development tax credits
|
| | | $ | 261 | | | | | $ | 200 | | |
Cash paid for interest
|
| | | $ | 6 | | | | | $ | 77 | | |
Supplemental disclosure of noncash flow information: | | | | | | | | | | | | | |
Noncash acquisition of fixed assets
|
| | | $ | 136 | | | | | $ | — | | |
| | |
Revenue
|
| |
Accounts receivable
|
| ||||||
|
For the year ended
December 31, 2020 |
| |
As of
December 31, 2020 |
| ||||||||
Customer A
|
| | | | 21% | | | | | | 4% | | |
Customer B
|
| | | | 21% | | | | | | 0% | | |
Customer C
|
| | | | 20% | | | | | | 53% | | |
Customer D
|
| | | | 14% | | | | | | 32% | | |
Customer E
|
| | | | 11% | | | | | | 0% | | |
Property and equipment
|
| |
Estimated
useful life |
|
Laboratory equipment
|
| |
5
|
|
Research devices
|
| |
5
|
|
Computer equipment
|
| |
5
|
|
Tooling
|
| |
3
|
|
Leased devices
|
| |
5
|
|
Other
|
| |
3 – 7
|
|
| | |
Pattern of
Recognition |
| |
2020
|
| |
2019
|
| ||||||
Device
|
| |
Point in time
|
| | | $ | 200 | | | | | $ | — | | |
Service
|
| |
Overtime
|
| | | | 94 | | | | | | — | | |
Total revenue
|
| | | | | | $ | 294 | | | | | $ | — | | |
| | |
2020
|
| |
2019
|
| ||||||
Accounts receivable
|
| | | | 174 | | | | | | — | | |
Deferred revenue, current
|
| | | | 158 | | | | | | — | | |
| | |
2020
|
| |
2019
|
| ||||||
Laboratory equipment
|
| | | $ | 572 | | | | | $ | 397 | | |
Research devices
|
| | | | 486 | | | | | | — | | |
Computer equipment
|
| | | | 385 | | | | | | 323 | | |
Construction in progress
|
| | | | 613 | | | | | | 18 | | |
Tooling
|
| | | | 270 | | | | | | 21 | | |
Leased devices
|
| | | | 127 | | | | | | — | | |
Other
|
| | | | 167 | | | | | | 157 | | |
| | | | | 2,620 | | | | | | 916 | | |
Less: Accumulated depreciation and amortization
|
| | | | (716) | | | | | | (427) | | |
Property and equipment, net
|
| | | $ | 1,904 | | | | | $ | 489 | | |
| | |
2020
|
| |
2019
|
| ||||||
Bonus
|
| | | $ | 501 | | | | | $ | 110 | | |
Contracted services
|
| | | | 456 | | | | | | 152 | | |
Legal fees
|
| | | | 282 | | | | | | 228 | | |
Other
|
| | | | 25 | | | | | | 1 | | |
Total accrued expenses and other current liabilities
|
| | | $ | 1,264 | | | | | $ | 491 | | |
Class
|
| |
Year of Class
Issuance |
| |
Issuance
Price per share |
| |
Shares
Authorized |
| |
Shares
Issued and Outstanding |
| |
Total
Proceeds or Exchange Value |
| |
Issuance
Costs |
| |
Net Carrying
Value |
| |
Initial
Liquidation Price per share |
| |||||||||||||||||||||
Series A
|
| |
2014
|
| | | $ | 0.04 | | | | | | 25,000,000 | | | | | | 25,000,000 | | | | | $ | 1,000 | | | | | $ | 2 | | | | | $ | 999 | | | | | $ | 0.80 | | |
Series B
|
| |
2017
|
| | | | 0.80 | | | | | | 10,625,000 | | | | | | 10,625,000 | | | | | | 8,500 | | | | | | — | | | | | | 8,500 | | | | | | 0.80 | | |
Series C
|
| |
2017
|
| | | | 1.88 | | | | | | 31,586,210 | | | | | | 31,586,210 | | | | | | 59,382 | | | | | | 234 | | | | | | 59,148 | | | | | | 1.88 | | |
Series D
|
| |
2020
|
| | | | 2.15 | | | | | | 62,577,618 | | | | | | 27,799,648 | | | | | | 59,769 | | | | | | 129 | | | | | | 59,640 | | | | | | 2.15 | | |
| | | | | | | | | | | | | | 129,788,828 | | | | | | 95,010,858 | | | | | | | | | | | | | | | | | | | | | | | | | | |
Class
|
| |
Year of Class
Issuance |
| |
Issuance
Price per share |
| |
Shares
Authorized |
| |
Shares
Issued and Outstanding |
| |
Total
Proceeds or Exchange Value |
| |
Issuance
Costs |
| |
Net Carrying
Value |
| |
Initial
Liquidation Price per share |
| |||||||||||||||||||||
Series A
|
| |
2014
|
| | | $ | 0.04 | | | | | | 25,000,000 | | | | | | 25,000,000 | | | | | $ | 1,000 | | | | | $ | 2 | | | | | $ | 999 | | | | | $ | 0.80 | | |
Series B
|
| |
2017
|
| | | | 0.80 | | | | | | 10,625,000 | | | | | | 10,625,000 | | | | | | 8,500 | | | | | | — | | | | | | 8,500 | | | | | | 0.80 | | |
Series C
|
| |
2017
|
| | | | 1.88 | | | | | | 31,914,894 | | | | | | 31,586,210 | | | | | | 59,382 | | | | | | 234 | | | | | | 59,148 | | | | | | 1.88 | | |
| | | | | | | | | | | | | | 67,539,894 | | | | | | 67,211,210 | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | |
Number of
Options |
| |
Weighted
Average Exercise Price |
| |
Weighted
Average Remaining Contractual Term |
| |
Aggregate
Intrinsic Value |
| ||||||||||||
Outstanding at December 31, 2019
|
| | | | 4,764,571 | | | | | $ | 0.74 | | | | | | 7.53 | | | | | $ | 2,313 | | |
Granted
|
| | | | 1,432,250 | | | | | | 1.23 | | | | | | | | | | | | | | |
Exercised
|
| | | | (206,784) | | | | | | 0.58 | | | | | | | | | | | | | | |
Forfeited
|
| | | | (177,887) | | | | | | 0.64 | | | | | | | | | | | | | | |
Outstanding at December 31, 2020
|
| | | | 5,812,150 | | | | | $ | 0.87 | | | | | | 7.07 | | | | | $ | 2,073 | | |
Options exercisable at December 31, 2020
|
| | | | 3,977,599 | | | | | $ | 0.76 | | | | | | 6.43 | | | | | $ | 1,879 | | |
Vested and expected to vest at December 31, 2020
|
| | | | 5,666,661 | | | | | $ | 0.87 | | | | | | 7.07 | | | | | $ | 5,667 | | |
| | |
2020
|
| |
2019
|
|
Risk Free interest rate
|
| |
1.5% – 1.7%
|
| |
1.5% – 2.7%
|
|
Expected dividend yield
|
| |
0%
|
| |
0%
|
|
Expected term
|
| |
5.8 years – 6.0 years
|
| |
5.9 years – 6.2 years
|
|
Expected volatility
|
| |
60%
|
| |
60%
|
|
| | |
2020
|
| |
2019
|
|
Risk Free interest rate
|
| |
1.5% – 1.7%
|
| |
1.5% – 2.7%
|
|
Expected dividend yield
|
| |
0%
|
| |
0%
|
|
Expected term
|
| |
5.8 years – 6.0 years
|
| |
4.7 years – 10.0 years
|
|
Expected volatility
|
| |
60%
|
| |
60%
|
|
| | |
2020
|
| |
2019
|
| ||||||
Research and development
|
| | | $ | 864 | | | | | $ | 596 | | |
General and administrative
|
| | | | 231 | | | | | | 293 | | |
Sales and marketing
|
| | | | 22 | | | | | | 7 | | |
Total stock-based compensation expense
|
| | | $ | 1,117 | | | | | $ | 896 | | |
| | |
2020
|
| |
2019
|
| ||||||
Numerator: | | | | | | | | | | | | | |
Net Loss
|
| | | $ | (23,427) | | | | | $ | (19,415) | | |
Numerator for Basic and Dilutive EPS – Loss available to common stockholders
|
| | | $ | (23,427) | | | | | $ | (19,415) | | |
Denominator: | | | | | | | | | | | | | |
Common Stock
|
| | | | 4,651,127 | | | | | | 4,486,484 | | |
Denominator for Basic and Dilutive EPS – Weighted-average common stock
|
| | | | 4,651,127 | | | | | | 4,486,484 | | |
Basic and dilutive loss per share
|
| | | $ | (5.04) | | | | | $ | (4.33) | | |
| | |
2020
|
| |
2019
|
| ||||||
Outstanding options to purchase common stock
|
| | | | 5,812,150 | | | | | | 4,764,571 | | |
Outstanding convertible preferred stock (Series A through D)
|
| | | | 95,010,858 | | | | | | 67,211,210 | | |
Total anti-dilutive common equivalent shares
|
| | | | 100,823,008 | | | | | | 71,975,781 | | |
| | |
As of December 31,
|
| |||||||||
| | |
2020
|
| |
2019
|
| ||||||
Gross deferred tax assets (liabilities): | | | | | | | | | | | | | |
Net operating loss carryforwards
|
| | | $ | 14,512 | | | | | $ | 11,976 | | |
Tax credit carryforwards
|
| | | | 2,237 | | | | | | 1,559 | | |
Fixed assets
|
| | | | 6 | | | | | | (46) | | |
Non-deductible stock-based compensation
|
| | | | 522 | | | | | | 485 | | |
Deferred Revenue
|
| | | | 421 | | | | | | — | | |
Other
|
| | | | 90 | | | | | | 85 | | |
Total Deferred tax assets
|
| | | $ | 17,788 | | | | | $ | 14,059 | | |
Valuation allowance
|
| | | | (17,788) | | | | | | (14,059) | | |
Net deferred tax assets (liabilities)
|
| | | $ | — | | | | | $ | — | | |
| | |
Years Ended December 31,
|
| |||||||||
|
2020
|
| |
2019
|
| ||||||||
Federal statutory income tax rate
|
| | | | 21.0% | | | | | | 21.0% | | |
State taxes, net of federal benefit
|
| | | | 1.8% | | | | | | 6.4% | | |
Federal research and development credits
|
| | | | 3.2% | | | | | | 4.0% | | |
Non-deductible stock-based compensation
|
| | | | (0.5)% | | | | | | (0.5)% | | |
Write down of federal NOL due to 382 limitation
|
| | | | (2.8)% | | | | | | — | | |
Write down of federal R&D credits due to 382 limitation
|
| | | | (1.1)% | | | | | | — | | |
Deferred tax adjustment resulting from tax rate change
|
| | | | (5.5)% | | | | | | — | | |
Other
|
| | | | (0.2)% | | | | | | (0.2)% | | |
Valuation allowance
|
| | | | (15.9)% | | | | | | (30.7)% | | |
Effective Tax Rate
|
| | | | 0.0% | | | | | | 0.0% | | |
| | |
Hyperfine
|
| ||||||
| | |
Amount
|
| |
Expire Through
|
| |||
Tax net operating loss carryforwards: | | | | | | | | | | |
Federal (pre-2018 NOLs)
|
| | | $ | 12,084 | | | |
2037
|
|
Federal (post-2017 NOLs)
|
| | | | 43,345 | | | |
No Expiration
|
|
States
|
| | | | 42,752 | | | |
2040
|
|
States
|
| | | | 24 | | | |
2030
|
|
Tax credit carryforwards: | | | | | | | | | | |
Federal research and development
|
| | | | 1,561 | | | |
2040
|
|
Connecticut research and development
|
| | | | 464 | | | |
N/A
|
|
Connecticut other
|
| | | | 14 | | | |
2025
|
|
| | |
Liminal
|
| ||||||
|
Amount
|
| |
Expire Through
|
| |||||
Tax net operating loss carryforwards: | | | | | | | | | | |
Federal (pre-2018 NOLs)
|
| | | $ | — | | | |
2037
|
|
Federal (post-2017 NOLs)
|
| | | | 6,170 | | | |
No Expiration
|
|
Connecticut
|
| | | | 6,170 | | | |
2040
|
|
Tax credit carryforwards: | | | | | | | | | | |
Federal research and development
|
| | | | 271 | | | |
2040
|
|
Connecticut research and development
|
| | | | 35 | | | |
N/A
|
|
Connecticut other
|
| | | | — | | | |
2025
|
|
| | |
September 30,
2021 |
| |
December 31,
2020 |
| ||||||
ASSETS | | | | | | | | | | | | | |
CURRENT ASSETS: | | | | | | | | | | | | | |
Cash and cash equivalents
|
| | | $ | 65,475 | | | | | $ | 62,676 | | |
Restricted cash
|
| | | | 3,467 | | | | | | 1,610 | | |
Accounts receivable, less allowance of $58 and $- in 2021 and 2020, respectively
|
| | | | 940 | | | | | | 174 | | |
Unbilled receivables
|
| | | | 48 | | | | | | — | | |
Inventory
|
| | | | 2,763 | | | | | | 1,718 | | |
Prepaid expenses and other current assets
|
| | | | 3,600 | | | | | | 691 | | |
Due from related parties
|
| | | | 13 | | | | | | 1,465 | | |
Total current assets
|
| | | $ | 76,306 | | | | | $ | 68,334 | | |
Property and equipment
|
| | | | 3,325 | | | | | | 1,904 | | |
Other assets – related party
|
| | | | 1,086 | | | | | | 1,244 | | |
Net investment in lease
|
| | | | 37 | | | | | | 44 | | |
Other long term assets
|
| | | | 614 | | | | | | — | | |
Total assets
|
| | | $ | 81,368 | | | | | $ | 71,526 | | |
LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS‘ DEFICIT | | | | | | | | | | | | | |
CURRENT LIABILITIES: | | | | | | | | | | | | | |
Accounts payable
|
| | | $ | 4,945 | | | | | $ | 948 | | |
Deferred grant funding
|
| | | | 3,467 | | | | | | 1,610 | | |
Deferred revenue
|
| | | | 774 | | | | | | 158 | | |
Due to related parties
|
| | | | 1,334 | | | | | | 136 | | |
Accrued expenses and other current liabilities
|
| | | | 3,294 | | | | | | 1,264 | | |
Total current liabilities
|
| | | $ | 13,814 | | | | | $ | 4,116 | | |
Long term notes payable
|
| | | | 178 | | | | | | 178 | | |
Long term deferred revenue
|
| | | | 340 | | | | | | — | | |
Total liabilities
|
| | | $ | 14,332 | | | | | $ | 4,294 | | |
COMMITMENTS AND CONTINGENCIES (NOTE 15) | | | | | | | | | | | | | |
CONVERTIBLE PREFERRED STOCK | | | | | | | | | | | | | |
Hyperfine convertible preferred stock (Series A, B, C and D): $.0001 par value, aggregate liquidation
preference of $178,120 and $147,651; 129,788,828 and 129,788,828 shares authorized; 109,182,191 and 95,010,858 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively |
| | | | 158,747 | | | | | | 128,286 | | |
Liminal convertible preferred stock (Series A-1 and A-2): $.0001 par value, aggregate liquidation
preference of $7,400,250; 57,500,000 shares authorized; 57,500,000 shares issued and outstanding at September 30, 2021 |
| | | | 9,350 | | | | | | — | | |
STOCKHOLDERS‘ DEFICIT: | | | | | | | | | | | | | |
Hyperfine Common stock, $.0001 par value; 125,000,000 and 125,000,000 shares authorized; 6,503,073 and 4,812,083 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively
|
| | | | 1 | | | | | | — | | |
Liminal Common stock, $.001 par value; 36,000,000 and 5,000 shares authorized; 0 and 1,000 shares
issued and outstanding at September 30, 2021 and December 31, 2020, respectively |
| | | | — | | | | | | — | | |
Hyperfine Special-voting common stock, $.0001 par value; 25,000,000 shares authorized; 0 shares issued and outstanding
|
| | | | — | | | | | | — | | |
Liminal Special-voting common stock, $.0001 par value; 38,723,398 shares authorized; 0 shares issued and outstanding at September 30, 2021
|
| | | | — | | | | | | — | | |
Additional paid-in capital
|
| | | | 9,173 | | | | | | 10,415 | | |
Accumulated deficit
|
| | | | (110,235) | | | | | | (71,469) | | |
Total stockholders’ deficit
|
| | | $ | (101,061) | | | | | $ | (61,054) | | |
TOTAL LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS‘ DEFICIT
|
| | | $ | 81,368 | | | | | $ | 71,526 | | |
| | |
Nine Months Ended September 30,
|
| |||||||||
| | |
2021
|
| |
2020
|
| ||||||
Sales | | | | | | | | | | | | | |
Device
|
| | | $ | 521 | | | | | $ | 77 | | |
Service
|
| | | | 539 | | | | | | 10 | | |
Total sales
|
| | | $ | 1,060 | | | | | $ | 87 | | |
Cost of sales | | | | | | | | | | | | | |
Device
|
| | | $ | 1,420 | | | | | $ | 368 | | |
Service
|
| | | | 354 | | | | | | — | | |
Total cost of sales
|
| | | $ | 1,774 | | | | | $ | 368 | | |
Gross margin
|
| | | | (714) | | | | | | (281) | | |
Operating Expenses: | | | | | | | | | | | | | |
Research and development
|
| | | $ | 16,949 | | | | | $ | 11,042 | | |
General and administrative
|
| | | | 15,348 | | | | | | 3,781 | | |
Sales and marketing
|
| | | | 5,770 | | | | | | 1,527 | | |
Total operating expenses
|
| | | | 38,067 | | | | | | 16,350 | | |
Loss from operations
|
| | | $ | (38,781) | | | | | $ | (16,631) | | |
Interest income
|
| | | $ | 13 | | | | | $ | 66 | | |
Other income, net
|
| | | | 2 | | | | | | — | | |
Loss before provision for income taxes
|
| | | $ | (38,766) | | | | | $ | (16,565) | | |
Provision for income taxes
|
| | | | — | | | | | | — | | |
Net loss and comprehensive loss
|
| | | $ | (38,766) | | | | | $ | (16,565) | | |
Net loss per common share attributable to common stockholders, basic and diluted
|
| | | $ | (7.41) | | | | | $ | (3.58) | | |
Weighted-average shares used to compute net loss per share attributable to
common stockholders, basic and diluted |
| | | | 5,229,877 | | | | | | 4,630,574 | | |
| | |
Hyperfine Convertible
Preferred Stock |
| |
Liminal Convertible
Preferred Stock |
| | |
Hyperfine Common
Stock |
| |
Liminal Common
Stock |
| |
Additional
Paid-in Capital |
| |
Accumulated
Deficit |
| |
Total
Stockholders’ Deficit |
| |||||||||||||||||||||||||||||||||||||||||||||
|
Shares
|
| |
Amount
|
| |
Shares
|
| |
Amount
|
| | |
Shares
|
| |
Amount
|
| |
Shares
|
| |
Amount
|
| ||||||||||||||||||||||||||||||||||||||||||||
December 31, 2019
|
| | | | 67,211,210 | | | | | $ | 68,646 | | | | | | — | | | | | $ | — | | | | | | | 4,605,299 | | | | | $ | — | | | | | | 1,000 | | | | | $ | — | | | | | $ | 8,178 | | | | | $ | (48,042) | | | | | $ | (39,864) | | |
Net loss
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (16,565) | | | | | | (16,565) | | |
Investment from 4Bionics, LLC
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 500 | | | | | | — | | | | | | 500 | | |
Exercise of stock options
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | | 90,341 | | | | | | — | | | | | | — | | | | | | — | | | | | | 64 | | | | | | — | | | | | | 64 | | |
Stock-based compensation expense
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 857 | | | | | | — | | | | | | 857 | | |
Balance, September 30, 2020
|
| | | | 67,211,210 | | | | | $ | 68,646 | | | | | | — | | | | | $ | — | | | | | | | 4,695,640 | | | | | $ | — | | | | | | 1,000 | | | | | $ | — | | | | | $ | 9,599 | | | | | $ | (64,607) | | | | | $ | (55,008) | | |
| | |
Hyperfine Convertible
Preferred Stock |
| |
Liminal Convertible
Preferred Stock |
| | |
Hyperfine Common
Stock |
| |
Liminal Common
Stock |
| |
Additional
Paid-in Capital |
| |
Accumulated
Deficit |
| |
Total
Stockholders’ Deficit |
| |||||||||||||||||||||||||||||||||||||||||||||
|
Shares
|
| |
Amount
|
| |
Shares
|
| |
Amount
|
| | |
Shares
|
| |
Amount
|
| |
Shares
|
| |
Amount
|
| ||||||||||||||||||||||||||||||||||||||||||||
December 31, 2020
|
| | | | 95,010,858 | | | | | $ | 128,286 | | | | | | — | | | | | $ | — | | | | | | | 4,812,083 | | | | | $ | — | | | | | | 1,000 | | | | | $ | — | | | | | $ | 10,415 | | | | | $ | (71,469) | | | | | $ | (61,054) | | |
Net loss
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (38,766) | | | | | | (38,766) | | |
Issuance of Series D convertible
|
| | | | 14,171,333 | | | | | | 30,461 | | | | | | — | | | | | | — | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
preferred stock, net of issuance
costs |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Investment from 4Bionics, LLC
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 3,516 | | | | | | — | | | | | | 3,516 | | |
Conversion of Liminal Common stock
|
| | | | — | | | | | | — | | | | | | 57,500,000 | | | | | | 9,350 | | | | | | | — | | | | | | — | | | | | | (1,000) | | | | | | — | | | | | | (9,350) | | | | | | — | | | | | | (9,350) | | |
Exercise of stock options
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | | 1,690,990 | | | | | | 1 | | | | | | — | | | | | | — | | | | | | 1,461 | | | | | | — | | | | | | 1,462 | | |
Stock-based compensation expense
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 3,131 | | | | | | — | | | | | | 3,131 | | |
Balance, September 30, 2021
|
| | | | 109,182,191 | | | | | $ | 158,747 | | | | | | 57,500,000 | | | | | $ | 9,350 | | | | | | | 6,503,073 | | | | | $ | 1 | | | | | | — | | | | | $ | — | | | | | $ | 9,173 | | | | | $ | (110,235) | | | | | $ | (101,061) | | |
| | |
Nine Months Ended September 30,
|
| |||||||||
| | |
2021
|
| |
2020
|
| ||||||
Cash flows from operating activities: | | | | | | | | | | | | | |
Net loss
|
| | | $ | (38,766) | | | | | $ | (16,565) | | |
Adjustments to reconcile net loss to net cash used in operating activities:
|
| | | | | | | | | | | | |
Depreciation and amortization
|
| | | | 389 | | | | | | 204 | | |
Stock-based compensation expense
|
| | | | 3,131 | | | | | | 857 | | |
Write-down of inventory
|
| | | | 19 | | | | | | 163 | | |
Payments received on net investment in lease
|
| | | | 7 | | | | | | — | | |
Changes in assets and liabilities:
|
| | | | | | | | | | | | |
Accounts receivable
|
| | | | (766) | | | | | | (58) | | |
Unbilled receivables
|
| | | | (48) | | | | | | — | | |
Inventory
|
| | | | (1,064) | | | | | | (1,404) | | |
Prepaid expenses and other current assets
|
| | | | (2,909) | | | | | | 261 | | |
Due from related parties
|
| | | | 1,452 | | | | | | 378 | | |
Other assets – related party
|
| | | | 158 | | | | | | 174 | | |
Prepaid inventory
|
| | | | — | | | | | | 649 | | |
Other long term assets
|
| | | | (614) | | | | | | — | | |
Accounts payable
|
| | | | 3,923 | | | | | | (112) | | |
Deferred grant funding
|
| | | | 1,857 | | | | | | 1,610 | | |
Deferred revenue
|
| | | | 956 | | | | | | 55 | | |
Due to related parties
|
| | | | 1,198 | | | | | | 2 | | |
Accrued expenses and other current liabilities
|
| | | | 2,030 | | | | | | 75 | | |
Net cash used in operating activities
|
| | | $ | (29,047) | | | | | $ | (13,711) | | |
Cash flows from investing activities: | | | | | | | | | | | | | |
Purchases of fixed assets
|
| | | | (1,736) | | | | | | (795) | | |
Net cash used in investing activities
|
| | | $ | (1,736) | | | | | $ | (795) | | |
Cash flows from financing activities: | | | | | | | | | | | | | |
Proceeds from exercise of stock options
|
| | | | 1,462 | | | | | | 64 | | |
Proceeds from issuance of Series D convertible preferred stock
|
| | | | 30,468 | | | | | | — | | |
Stock issuance costs related to Series D convertible preferred stock
|
| | | | (7) | | | | | | — | | |
Proceeds from issuance of notes payable
|
| | | | — | | | | | | 1,067 | | |
Investment from 4Bionics, LLC
|
| | | | 3,516 | | | | | | 500 | | |
Net cash provided by financing activities
|
| | | $ | 35,439 | | | | | $ | 1,631 | | |
Net increase (decrease) in cash and cash equivalents and restricted cash
|
| | | | 4,656 | | | | | | (12,875) | | |
Cash, cash equivalents and restricted cash, beginning of period
|
| | | | 64,286 | | | | | | 26,441 | | |
Cash, cash equivalents and restricted cash, end of period
|
| | | $ | 68,942 | | | | | $ | 13,566 | | |
Reconciliation of cash, cash equivalents, and restricted cash reported in the statement of financial position
|
| | | | | | | | | | | | |
Cash and cash equivalents
|
| | | $ | 65,475 | | | | | $ | 11,956 | | |
Restricted cash
|
| | | | 3,467 | | | | | | 1,610 | | |
Total cash, cash equivalents and restricted cash
|
| | | $ | 68,942 | | | | | $ | 13,566 | | |
Supplemental disclosure of cash flow information: | | | | | | | | | | | | | |
Cash received from exchange of research and development tax credits
|
| | | $ | 324 | | | | | $ | 523 | | |
| | |
Revenue
|
| |
Accounts receivable
|
| ||||||||||||||||||
| | |
For the nine months ended
September 30, 2021 |
| |
For the nine months ended
September 30, 2020 |
| |
As of
September 30, 2021 |
| |
As of
December 31, 2020 |
| ||||||||||||
Customer A
|
| | | | 11% | | | | | | 0% | | | | | | 6% | | | | | | 0% | | |
Customer B
|
| | | | 10% | | | | | | 60% | | | | | | 16% | | | | | | 0% | | |
Customer C
|
| | | | 10% | | | | | | 0% | | | | | | 0% | | | | | | 0% | | |
Customer D
|
| | | | 6% | | | | | | 0% | | | | | | 12% | | | | | | 0% | | |
Customer E
|
| | | | 6% | | | | | | 0% | | | | | | 12% | | | | | | 0% | | |
Customer F
|
| | | | 5% | | | | | | 0% | | | | | | 27% | | | | | | 0% | | |
Customer G
|
| | | | 3% | | | | | | 0% | | | | | | 0% | | | | | | 53% | | |
Customer H
|
| | | | 1% | | | | | | 40% | | | | | | 0% | | | | | | 32% | | |
| | |
Pattern of
Recognition |
| |
Nine Months Ended September 30,
|
| | |||||||||||
| | |
2021
|
| |
2020
|
| | |||||||||||
Device
|
| |
Point in time
|
| | | $ | 521 | | | | | $ | 77 | | | | ||
Service
|
| | Over time | | | | | 539 | | | | | | 10 | | | | ||
Total revenue
|
| | | | | | $ | 1,060 | | | | | $ | 87 | | | | | |
| | |
September 30,
2021 |
| |
December 31,
2020 |
| ||||||
Accounts receivable
|
| | | $ | 940 | | | | | $ | 174 | | |
Unbilled receivables
|
| | | | 48 | | | | | | — | | |
Deferred revenue
|
| | | | 774 | | | | | | 158 | | |
Long term deferred revenue
|
| | | | 340 | | | | | | — | | |
| | |
September 30,
2021 |
| |
December 31,
2020 |
| ||||||
Deferred transaction related costs
|
| | | $ | 3,042 | | | | | $ | — | | |
Prepaid expenses
|
| | | | 385 | | | | | | 203 | | |
Other current assets
|
| | | | 173 | | | | | | 488 | | |
Total prepaid expenses and other current assets
|
| | | $ | 3,600 | | | | | $ | 691 | | |
| | |
September 30,
2021 |
| |
December 31,
202 |
| ||||||
Laboratory equipment
|
| | | $ | 874 | | | | | $ | 572 | | |
Research devices
|
| | | | 772 | | | | | | 486 | | |
Sales and marketing devices
|
| | | | 762 | | | | | | — | | |
Computer equipment
|
| | | | 525 | | | | | | 385 | | |
Construction in progress
|
| | | | 686 | | | | | | 613 | | |
Tooling
|
| | | | 292 | | | | | | 270 | | |
Leased devices
|
| | | | 347 | | | | | | 127 | | |
Other
|
| | | | 172 | | | | | | 167 | | |
| | | | | 4,430 | | | | | | 2,620 | | |
Less: Accumulated depreciation and amortization
|
| | | | (1,105) | | | | | | (716) | | |
Property and equipment, net
|
| | | $ | 3,325 | | | | | $ | 1,904 | | |
| | |
September 30,
2021 |
| |
December 31,
2020 |
| ||||||
Bonus
|
| | | $ | 1,535 | | | | | $ | 501 | | |
Contracted services
|
| | | | 883 | | | | | | 456 | | |
Legal fees
|
| | | | 435 | | | | | | 282 | | |
Commission
|
| | | | 340 | | | | | | — | | |
Other
|
| | | | 101 | | | | | | 25 | | |
Total accrued expenses and other current liabilities
|
| | | $ | 3,294 | | | | | $ | 1,264 | | |
Class
|
| |
Year of Class
Issuance |
| |
Issuance
Price per Share |
| |
Shares
Authorized |
| |
Shares
Issued and Outstanding |
| |
Total
Proceeds or Exchange Value |
| |
Issuance
Costs |
| |
Net
Carrying Value |
| |
Initial
Liquidation Price per Share |
| |||||||||||||||||||||
Series A
|
| |
2014
|
| | | $ | 0.04 | | | | | | 25,000,000 | | | | | | 25,000,000 | | | | | $ | 1,000 | | | | | $ | 2 | | | | | $ | 998 | | | | | $ | 0.80 | | |
Series B
|
| |
2017
|
| | | | 0.80 | | | | | | 10,625,000 | | | | | | 10,625,000 | | | | | | 8,500 | | | | | | — | | | | | | 8,500 | | | | | | 0.80 | | |
Series C
|
| |
2017
|
| | | | 1.88 | | | | | | 31,586,210 | | | | | | 31,586,210 | | | | | | 59,382 | | | | | | 234 | | | | | | 59,148 | | | | | | 1.88 | | |
Series D
|
| |
2020 – 2021
|
| | | | 2.15 | | | | | | 62,577,618 | | | | | | 41,970,981 | | | | | | 90,237 | | | | | | 136 | | | | | | 90,101 | | | | | | 2.15 | | |
| | | | | | | | | | | | | | 129,788,828 | | | | | | 109,182,191 | | | | | $ | 159,119 | | | | | $ | 372 | | | | | $ | 158,747 | | | | | | | | |
Class
|
| |
Year of Class
Issuance |
| |
Issuance
Price per Share |
| |
Shares
Authorized |
| |
Shares
Issued and Outstanding |
| |
Total
Proceeds or Exchange Value |
| |
Issuance
Costs |
| |
Net
Carrying Value |
| |
Initial
Liquidation Price per Share |
| |||||||||||||||||||||
Series A
|
| |
2014
|
| | | $ | 0.04 | | | | | | 25,000,000 | | | | | | 25,000,000 | | | | | $ | 1,000 | | | | | $ | 2 | | | | | $ | 998 | | | | | $ | 0.80 | | |
Series B
|
| |
2017
|
| | | | 0.80 | | | | | | 10,625,000 | | | | | | 10,625,000 | | | | | | 8,500 | | | | | | — | | | | | | 8,500 | | | | | | 0.80 | | |
Series C
|
| |
2017
|
| | | | 1.88 | | | | | | 31,586,210 | | | | | | 31,586,210 | | | | | | 59,382 | | | | | | 234 | | | | | | 59,148 | | | | | | 1.88 | | |
Series D
|
| |
2020
|
| | | | 2.15 | | | | | | 62,577,618 | | | | | | 27,799,648 | | | | | | 59,769 | | | | | | 129 | | | | | | 59,640 | | | | | | 2.15 | | |
| | | | | | | | | | | | | | 129,788,828 | | | | | | 95,010,858 | | | | | $ | 128,651 | | | | | $ | 365 | | | | | $ | 128,286 | | | | | | | | |
| | |
Number of
Options |
| |
Weighted
Average Exercise Price |
| |
Weighted
Average Remaining Contractual Term |
| |
Aggregate
Intrinsic Value |
| ||||||||||||
Outstanding at December 31, 2020
|
| | | | 5,812,150 | | | | | $ | 0.87 | | | | | | 7.07 | | | | | $ | 2,073 | | |
Granted
|
| | | | 19,591,900 | | | | | | 1.07 | | | | | | | | | | | | | | |
Exercised
|
| | | | (1,690,990) | | | | | | 0.86 | | | | | | | | | | | | | | |
Forfeited
|
| | | | (1,047,555) | | | | | | 1.04 | | | | | | | | | | | | | | |
Outstanding at September 30, 2021
|
| | | | 22,665,505 | | | | | $ | 1.04 | | | | | | 9.03 | | | | | $ | 1,018 | | |
Options exercisable at September 30, 2021
|
| | | | 3,554,421 | | | | | $ | 0.83 | | | | | | 6.64 | | | | | $ | 964 | | |
Vested and expected to vest at September 30, 2021
|
| | | | 21,149,996 | | | | | $ | 1.03 | | | | | | 9.00 | | | | | $ | 1,014 | | |
| | |
Number of
Options |
| |
Weighted
Average Exercise Price |
| |
Weighted
Average Remaining Contractual Term |
| |
Aggregate
Intrinsic Value |
| ||||||||||||
Outstanding at December 31, 2020
|
| | | | — | | | | | $ | — | | | | | | — | | | | | $ | — | | |
Granted
|
| | | | 1,976,000 | | | | | | 0.94 | | | | | | | | | | | | | | |
Exercised
|
| | | | — | | | | | | — | | | | | | | | | | | | | | |
Forfeited
|
| | | | (1,006,250) | | | | | | 0.94 | | | | | | | | | | | | | | |
Outstanding at September 30, 2021
|
| | | | 969,750 | | | | | $ | 0.94 | | | | | | 9.61 | | | | | $ | — | | |
Options exercisable at September 30, 2021
|
| | | | 189,091 | | | | | $ | 0.94 | | | | | | 9.61 | | | | | $ | — | | |
Vested and expected to vest at September 30, 2021
|
| | | | 969,750 | | | | | $ | 0.94 | | | | | | 9.61 | | | | | $ | — | | |
| | |
Nine months ended September 30,
|
| |||||||||
| | |
2021
|
| |
2020
|
| ||||||
Cost of sales – Device
|
| | | $ | 12 | | | | | $ | — | | |
Cost of sales – Service
|
| | | | 12 | | | | | | — | | |
Research and development
|
| | | | 829 | | | | | | 655 | | |
General and administrative
|
| | | | 2,226 | | | | | | 131 | | |
Sales and marketing
|
| | | | 52 | | | | | | 71 | | |
| | | | $ | 3,131 | | | | | $ | 857 | | |
| | |
Nine Months Ended September 30,
|
| |||||||||
| | |
2021
|
| |
2020
|
| ||||||
Numerator: | | | | | | | | | | | | | |
Net Loss
|
| | | $ | (38,766) | | | | | $ | (16,565) | | |
Numerator for Basic and Dilutive EPS – Loss available to common stockholders
|
| | | $ | (38,766) | | | | | $ | (16,565) | | |
Denominator: | | | | | | | | | | | | | |
Common Stock
|
| | | | 5,229,877 | | | | | | 4,630,574 | | |
Denominator for Basic and Dilutive EPS – Weighted-average common stock
|
| | | | 5,229,877 | | | | | | 4,630,574 | | |
Basic and dilutive loss per share
|
| | | $ | (7.41) | | | | | $ | (3.58) | | |
| | |
Nine Months Ended September 30,
|
| |||||||||
| | |
2021
|
| |
2020
|
| ||||||
Outstanding options to purchase common stock
|
| | | | 23,635,255 | | | | | | 6,026,335 | | |
Outstanding Hyperfine convertible preferred stock (Series A through D)
|
| | | | 109,182,191 | | | | | | 67,211,210 | | |
Outstanding Liminal convertible preferred stock (Series A-1 and A-2)
|
| | | | 57,500,000 | | | | | | — | | |
Total anti-dilutive common equivalent shares
|
| | | | 190,317,446 | | | | | | 73,237,545 | | |
| | |
Page
|
| |||
| | | | A-7 | | | |
| | | | A-7 | | | |
| | | | A-23 | | | |
| | | | A-23 | | | |
| | | | A-25 | | | |
| | | | A-25 | | | |
| | | | A-26 | | | |
| | | | A-26 | | | |
| | | | A-27 | | | |
| | | | A-28 | | | |
| | | | A-28 | | | |
| | | | A-29 | | | |
| | | | A-30 | | | |
| | | | A-30 | | | |
| | | | A-30 | | | |
| | | | A-32 | | | |
| | | | A-32 | | | |
| | | | A-33 | | | |
| | | | A-34 | | | |
| | | | A-34 | | | |
| | | | A-35 | | | |
| | | | A-35 | | | |
| | | | A-36 | | | |
| | | | A-36 | | | |
| | | | A-37 | | | |
| | | | A-37 | | | |
| | | | A-40 | | | |
| | | | A-40 | | | |
| | | | A-41 | | | |
| | | | A-42 | | | |
| | | | A-42 | | | |
| | | | A-43 | | | |
| | | | A-43 | | | |
| | | | A-43 | | | |
| | | | A-44 | | | |
| | | | A-44 | | | |
| | | | A-46 | | | |
| | | | A-46 | | | |
| | | | A-47 | | | |
| | | | A-47 | | |
| | |
Page
|
| |||
| | | | A-47 | | | |
| | | | A-48 | | | |
| | | | A-48 | | | |
| | | | A-48 | | | |
| | | | A-49 | | | |
| | | | A-49 | | | |
| | | | A-49 | | | |
| | | | A-50 | | | |
| | | | A-50 | | | |
| | | | A-51 | | | |
| | | | A-51 | | | |
| | | | A-51 | | | |
| | | | A-51 | | | |
| | | | A-51 | | | |
| | | | A-52 | | | |
| | | | A-53 | | | |
| | | | A-53 | | | |
| | | | A-54 | | | |
| | | | A-54 | | | |
| | | | A-55 | | | |
| | | | A-55 | | | |
| | | | A-57 | | | |
| | | | A-59 | | | |
| | | | A-60 | | | |
| | | | A-60 | | | |
| | | | A-61 | | | |
| | | | A-62 | | | |
| | | | A-63 | | | |
| | | | A-63 | | | |
| | | | A-64 | | | |
| | | | A-65 | | | |
| | | | A-65 | | | |
| | | | A-65 | | | |
| | | | A-66 | | | |
| | | | A-66 | | | |
| | | | A-67 | | | |
| | | | A-68 | | | |
| | | | A-68 | | | |
| | | | A-69 | | | |
| | | | A-69 | | |
| | |
Page
|
| |||
| | | | A-69 | | | |
| | | | A-69 | | | |
| | | | A-70 | | | |
| | | | A-70 | | | |
| | | | A-71 | | | |
| | | | A-71 | | | |
| | | | A-71 | | | |
| | | | A-72 | | | |
| | | | A-73 | | | |
| | | | A-73 | | | |
| | | | A-73 | | | |
| | | | A-73 | | | |
| | | | A-73 | | | |
| | | | A-74 | | | |
| | | | A-74 | | | |
| | | | A-74 | | | |
| | | | A-75 | | | |
| | | | A-75 | | | |
| | | | A-75 | | | |
| | | | A-75 | | | |
| | | | A-76 | | | |
| | | | A-76 | | | |
| | | | A-76 | | | |
| | | | A-76 | | | |
| | | | A-77 | | | |
| | | | A-77 | | | |
| | | | A-78 | | |
|
Schedule A
PIPE Investors
|
| | ||
|
Schedule B
Supporting Company Persons
|
| | | |
|
Schedule C
Required Governing Documents Proposals
|
| | ||
|
Exhibit A
Form of Parent Certificate of Incorporation
|
| | ||
|
Exhibit B
Form of Parent Bylaws
|
| | ||
|
Exhibit C
Form of PIPE Investor Subscription Agreement
|
| | ||
|
Exhibit D
Form of Advisory Agreement
|
| | ||
|
Exhibit E
Form of Registration Rights Agreement
|
| | ||
|
Exhibit F
Form of Transaction Support Agreement
|
| | ||
|
Exhibit G
Form of Parent Incentive Equity Plan
|
| |
|
“Affiliate”
|
| | in respect of a person, means any other person that, directly or indirectly, through one or more intermediaries, controls, is controlled by, or is under common control with, such person, and (a) in the case of a natural person, shall include, without limitation, such person’s spouse, parents, children, siblings, mother-in-law and father-in-law and brothers and sisters-in-law, whether by blood, marriage or adoption or anyone residing in such person’s home, a trust for the benefit of any of the foregoing, a company, partnership or any natural person or entity wholly or jointly owned by any of the foregoing and (b) in the case of an entity, shall include a partnership, a corporation or any natural person or entity which directly, or indirectly through one or more intermediaries, controls, is controlled by, or is under common control with, such entity. | |
|
“Applicable Law”
|
| | means, with respect to any person, all provisions of laws, statutes, ordinances, rules, regulations, permits, certificates, judgments, decisions, decrees or orders of any governmental authority applicable to such person. | |
|
“Articles”
|
| | means these amended and restated articles of association of the Company. | |
|
“Audit Committee”
|
| | means the audit committee of the board of directors of the Company established pursuant to the Articles, or any successor committee. | |
|
“Auditor”
|
| | means the person for the time being performing the duties of auditor of the Company (if any). | |
|
“Business Combination”
|
| | means a merger, share exchange, asset acquisition, share purchase, reorganisation or similar business combination involving the Company, with one or more businesses or entities (the “target business”), which Business Combination: (a) as long as the securities of the Company are listed on the Nasdaq Capital Market, must occur with one or more target businesses that together have an aggregate fair market value of at least 80 per cent of the assets held in the Trust Account (excluding the amount of deferred underwriting discounts held in trust and taxes payable on the interest earned on the Trust Account) at the time of the signing of the definitive agreement to enter into such Business Combination; and (b) must not be solely effectuated with another blank cheque company or a similar company with nominal operations. | |
|
“business day”
|
| | means any day other than a Saturday, a Sunday or a legal holiday or a | |
| | | | day on which banking institutions or trust companies are authorised or obligated by law to close in New York City. | |
|
“Clearing House”
|
| | means a clearing house recognised by the laws of the jurisdiction in which the Shares (or depositary receipts therefor) are listed or quoted on a stock exchange or interdealer quotation system in such jurisdiction. | |
|
“Class A Share”
|
| | means a Class A ordinary share of a par value of US$0.0001 in the share capital of the Company. | |
|
“Class B Share”
|
| | means a Class B ordinary share of a par value of US$0.0001 in the share capital of the Company. | |
|
“Company”
|
| | means the above named company. | |
|
“Company’s Website”
|
| | means the website of the Company and/or its web-address or domain name (if any). | |
|
“Compensation Committee”
|
| | means the compensation committee of the board of directors of the Company established pursuant to the Articles, or any successor committee. | |
|
“Designated Stock Exchange”
|
| | means any United States national securities exchange on which the securities of the Company are listed for trading, including the New York Stock Exchange or the Nasdaq Capital Market. | |
|
“Directors”
|
| | means the directors for the time being of the Company. | |
|
“Dividend”
|
| | means any dividend (whether interim or final) resolved to be paid on Shares pursuant to the Articles. | |
|
“Electronic Communication”
|
| | means a communication sent by electronic means, including electronic posting to the Company’s Website, transmission to any number, address or internet website (including the website of the Securities and Exchange Commission) or other electronic delivery methods as otherwise decided and approved by the Directors. | |
|
“Electronic Record”
|
| | has the same meaning as in the Electronic Transactions Act. | |
|
“Electronic Transactions Act”
|
| | means the Electronic Transactions Act (As Revised) of the Cayman Islands. | |
|
“Equity-linked Securities”
|
| | means any debt or equity securities that are convertible, exercisable or exchangeable for Class A Shares issued in a financing transaction in connection with a Business Combination, including but not limited to a private placement of equity or debt. | |
|
“Exchange Act”
|
| | means the United States Securities Exchange Act of 1934, as amended, or any similar U.S. federal statute and the rules and regulations of the Securities and Exchange Commission thereunder, all as the same shall be in effect at the time. | |
|
“Founders”
|
| | means all Members immediately prior to the consummation of the IPO. | |
|
“Independent Director”
|
| | has the same meaning as in the rules and regulations of the Designated Stock Exchange or in Rule 10A-3 under the Exchange Act, as the case may be. | |
|
“IPO”
|
| | means the Company’s initial public offering of securities. | |
|
“Member”
|
| | has the same meaning as in the Statute. | |
|
“Memorandum”
|
| | means the amended and restated memorandum of association of the Company. | |
|
“Nominating and Corporate Governance Committee”
|
| | means the nominating and corporate governance committee of the board of directors of the Company established pursuant to the Articles, or any successor committee. | |
|
“Officer”
|
| | means a person appointed to hold an office in the Company. | |
|
“Ordinary Resolution”
|
| | means a resolution passed by a simple majority of the Members as, being entitled to do so, vote in person or, where proxies are allowed, by proxy at a general meeting, and includes a unanimous written resolution. In computing the majority when a poll is demanded regard shall be had to the number of votes to which each Member is entitled by the Articles. | |
|
“Over-Allotment Option”
|
| | means the option of the Underwriters to purchase up to an additional 15 per cent of the firm Class A Shares issued in the IPO at a price equal to US$10 per Class A Share, less underwriting discounts and commissions. | |
|
“Preference Share”
|
| | means a preference share of a par value of US$0.0001 in the share capital of the Company. | |
|
“Public Share”
|
| | means a Class A Share issued in the IPO. | |
|
“Redemption Notice”
|
| | means a notice in a form approved by the Company by which a holder of Public Shares is entitled to require the Company to redeem its Public Shares, subject to any conditions contained therein. | |
|
“Register of Members”
|
| | means the register of Members maintained in accordance with the Statute and includes (except where otherwise stated) any branch or duplicate register of Members. | |
|
“Registered Office”
|
| | means the registered office for the time being of the Company. | |
|
“Representative”
|
| | means a representative of the Underwriters. | |
|
“Seal”
|
| | means the common seal of the Company and includes every duplicate seal. | |
|
“Securities and Exchange Commission”
|
| |
means the United States Securities and Exchange Commission.
|
|
|
“Share”
|
| | means a Class A Share, a Class B Share or a Preference Share and includes a fraction of a share in the Company. | |
|
“Special Resolution”
|
| | subject to Article 29.4, has the same meaning as in the Statute, and includes a unanimous written resolution. | |
|
“Sponsor”
|
| | means HC Sponsor LLC, a Cayman Islands limited liability company, and its successors or assigns. | |
|
“Statute”
|
| | means the Companies Act (As Revised) of the Cayman Islands. | |
|
“Treasury Share”
|
| | means a Share held in the name of the Company as a treasury share in accordance with the Statute. | |
|
“Trust Account”
|
| | means the trust account established by the Company upon the consummation of its IPO and into which a certain amount of the net proceeds of the IPO, together with a certain amount of the proceeds of a private placement of Class A Shares simultaneously with the closing date of the IPO, will be deposited. | |
|
“Underwriter”
|
| | means an underwriter of the IPO from time to time and any successor underwriter. | |
| | | | | D-4 | | | |
| | | | | D-4 | | | |
| | | | | D-4 | | | |
| | | | | D-4 | | | |
| | | | | D-4 | | | |
| | | | | D-4 | | | |
| | | | | D-5 | | | |
| | | | | D-5 | | | |
| | | | | D-5 | | | |
| | | | | D-5 | | | |
| | | | | D-6 | | | |
| | | | | D-8 | | | |
| | | | | D-11 | | | |
| | | | | D-11 | | | |
| | | | | D-11 | | | |
| | | | | D-12 | | | |
| | | | | D-12 | | | |
| | | | | D-12 | | | |
| | | | | D-12 | | | |
| | | | | D-12 | | | |
| | | | | D-12 | | | |
| | | | | D-12 | | | |
| | | | | D-12 | | | |
| | | | | D-12 | | | |
| | | | | D-12 | | | |
| | | | | D-12 | | | |
| | | | | D-13 | | | |
| | | | | D-13 | | | |
| | | | | D-13 | | | |
| | | | | D-13 | | | |
| | | | | D-13 | | | |
| | | | | D-13 | | | |
| | | | | D-13 | | | |
| | | | | D-13 | | | |
| | | | | D-13 | | | |
| | | | | D-13 | | | |
| | | | | D-14 | | | |
| | | | | D-14 | | | |
| | | | | D-14 | | | |
| | | | | D-14 | | |
| | | | | D-14 | | | |
| | | | | D-14 | | | |
| | | | | D-14 | | | |
| | | | | D-15 | | | |
| | | | | D-15 | | | |
| | | | | D-15 | | | |
| | | | | D-15 | | | |
| | | | | D-15 | | | |
| | | | | D-16 | | | |
| | | | | D-16 | | | |
| | | | | D-16 | | | |
| | | | | D-16 | | | |
| | | | | D-16 | | | |
| | | | | D-16 | | | |
| | | | | D-16 | | | |
| | | | | D-17 | | | |
| | | | | D-17 | | | |
| | | | | D-17 | | | |
| | | | | D-17 | | | |
| | | | | D-17 | | | |
| | | | | D-17 | | | |
| | | | | D-17 | | | |
| | | | | D-17 | | | |
| | | | | D-17 | | | |
| | | | | D-18 | | | |
| | | | | D-18 | | | |
| | | | | D-18 | | | |
| | | | | D-19 | | | |
| | | | | D-19 | | | |
| | | | | D-19 | | | |
| | | | | D-19 | | | |
| | | | | D-19 | | | |
| | | | | D-19 | | | |
| | | | | D-20 | | |
| If to the Company, to: | | | with copies (which shall not constitute notice) to: | |
| HealthCor Catalio Acquisition Corp. | | | Kirkland & Ellis LLP | |
| 55 Hudson Yards, 28th Floor | | | 609 Main Street | |
| New York, NY 10001 | | | Houston, TX 77002 | |
| Attn: Anabelle Perez Gray | | | Attn: Debbie P. Yee, P.C. | |
| Email: anabelle@hccspac.com | | | Email: debbie.yee@kirkland.com | |
| Telephone No.: (212) 622-7800 | | | Telephone No.: (713) 836-3600 | |
Name(s) of Subscriber: |
|
Signature of Authorized Signatory of Subscriber: |
|
Name of Authorized Signatory: |
|
Title of Authorized Signatory: |
|
Attention: |
|
Email: |
|
Facsimile No.: |
|
Telephone No.: |
|
| ☐ Limited Partnership | | | ☐ General Partnership | |
| ☐ Corporation | | | ☐ Revocable Trust | |
| ☐ Other Type of Trust (indicate type): | | |
|
|
| ☐ Other (indicate form of organization): | | |
|
|
| If to the Company, to: | | | with copies (which shall not constitute notice) to: | |
| HealthCor Catalio Acquisition Corp. | | | Kirkland & Ellis LLP | |
| 55 Hudson Yards, 28th Floor | | | 609 Main Street | |
| New York, NY 10001 | | | Houston, TX 77002 | |
| Attn: Anabelle Perez Gray | | | Attn: Debbie P. Yee, P.C. | |
| Email: anabelle@hccspac.com | | | Email: debbie.yee@kirkland.com | |
| Telephone No.: (212) 622-7800 | | | Telephone No.: (713) 836-3600 | |
Name(s) of Subscriber: |
|
Signature of Authorized Signatory of Subscriber: |
|
Name of Authorized Signatory: |
|
Title of Authorized Signatory: |
|
Attention: |
|
Email: |
|
Facsimile No.: |
|
Telephone No.: |
|
| ☐ Individual | | | ☐ Limited Partnership | |
| ☐ Corporation | | | ☐ General Partnership | |
| ☐ Revocable Trust | | | | |
| ☐ Other Type of Trust (indicate type): | | |
|
|
| ☐ Other (indicate form of organization): | | |
|
|
| SPONSOR GROUP HOLDERS: | | | | | |||
|
HC SPONSOR LLC,
a Cayman Islands limited liability company |
| | | | |||
| | | | | | | | |
| By: | | |
|
| | | |
| Name: | | |
|
| | | |
| Title: | | |
|
| | | |
|
Michael Weinstein
|
| | |||||
|
Christopher Wolfgang
|
| | |||||
|
Taylor Harris
|
| |
|
Jonathan M. Rothberg
|
| | ELIZABETH A. WHAYLAND AND GREGORY T. MULHERN, AS JOINT TENANTS WITH RIGHT OF SURVIVORSHIP | |
|
Scott Huennekens
|
| |
Name: Elizabeth A. Whayland
|
|
|
Ruth Fattori
|
| |
Name: Gregory T. Mulhern
|
|
|
David Scott
|
| | | |
|
Daguang Wang
|
| | | |
|
Mark Hughes
|
| | | |
|
Khan Siddiqui
|
| | | |
|
Neela Paykel
|
| | | |
|
Dan Wolterman
|
| | | |
|
John Dahldorf
|
| | | |
|
Elizabeth A. Whayland
|
| | | |
|
HYPERFINE HOLDERS:
|
| | YONGHUA INTERNATIONAL I L.P. | | ||||||
| JONATHAN M. ROTHBERG CHILDREN’S TRUST 2012 | | | By: | | |
|
| |||
| | | | | | | | | | | |
| By: | | |
|
| | Name: | | |
|
|
| Name: | | |
|
| | Title: | | |
|
|
| Title: | | |
|
| | YONGHUA INTERNATIONAL II L.P. | | |||
| 23RD CENTURY CAPITAL LLC | | | By: | | |
|
| |||
| By: | | |
|
| | Name: | | |
|
|
| Name: | | |
|
| | Title: | | |
|
|
| Title: | | |
|
| | FOSUN INDUSTRIAL CO., LIMITED | | |||
| ROTHBERG FAMILY FUND I, LLC | | | By: | | |
|
| |||
| By: | | |
|
| | Name: | | |
|
|
| Name: | | |
|
| | Title: | | |
|
|
| Title: | | |
|
| | MONASHEE SOLITARIO FUND LP | | |||
| HILDRED HOLDINGS, LLC (SERIES F) | | | By: | | |
|
| |||
| By: | | |
|
| | Name: | | |
|
|
| Name: | | |
|
| | Title: | | |
|
|
| Title: | | |
|
| | CD-VENTURE GMBH | | |||
| YH NORTH AMERICA CAPITAL L.P. | | | By: | | |
|
| |||
| By: | | |
|
| | Name: | | |
|
|
| Name: | | |
|
| | Title: | | |
|
|
| Title: | | |
|
| | | | |
|
HYPERFINE HOLDERS:
|
| | CRYPTOS LLC | | ||||||
| | | | | | | | | | | |
| AMB PROPRTY (PROVIDENCE) PTY LTD | | | By: | | |
|
| |||
| By: | | |
|
| | Name: | | |
|
|
| Name: | | |
|
| | Title: | | |
|
|
| Title: | | |
|
| | DAVID DOLBY INVESTMENTS II LLC | | |||
| ALBANY PRIVATE EQUITY PTY LTD | | | By: | | |
|
| |||
| By: | | |
|
| | Name: | | |
|
|
| Name: | | |
|
| | Title: | | |
|
|
| Title: | | |
|
| | DOLBY FAMILY VENTURES, L.P. | | |||
| KCLAVIS-NEXTRANS FUND NO.1 | | | By: | | |
|
| |||
| By: | | |
|
| | Name: | | |
|
|
| Name: | | |
|
| | Title: | | |
|
|
| Title: | | |
|
| | GV 2019, L.P. | | |||
| JSR LIMITED | | | By: | | |
|
| |||
| By: | | |
|
| | Name: | | |
|
|
| Name: | | |
|
| | Title: | | |
|
|
| Title: | | |
|
| | | | | ||
| GUILFORD ASIA LIMITED | | | | | ||||||
| By: | | |
|
| | | | | ||
| Name: | | |
|
| | | | | ||
| Title: | | |
|
| | | | |
|
HYPERFINE HOLDERS:
|
| | VENDIHOLD SA | | ||||||
| EQC PRIVATE MARKETS SAC FUND — EQC MEDDEV FUND | | | By: | | |
|
| |||
| | | | | | | | | | | |
| By: | | |
|
| | Name: | | |
|
|
| Name: | | |
|
| | Title: | | |
|
|
| Title: | | |
|
| | | | | ||
| OPALEYE, L.P. | | | | | | |||||
| | | | | | | | | | | |
| By: | | |
|
| | | | | ||
| Name: | | |
|
| | | | | ||
| Title: | | |
|
| | | | | ||
| SMALL VENTURES USA, LP | | | | | | |||||
| | | | | | | | | | | |
| By: | | |
|
| | | | | ||
| Name: | | |
|
| | | | | ||
| Title: | | |
|
| | | | | ||
| ZEPP INVESTMENT PLATFORM I LTD. | | | | | | |||||
| | | | | | | | | | | |
| By: | | |
|
| | | | | ||
| Name: | | |
|
| | | | | ||
| Title: | | |
|
| | | | | ||
| ACADIA WOODS PARTNERS, LLC | | | | | | |||||
| | | | | | | | | | | |
| By: | | |
|
| | | | | ||
| Name: | | |
|
| | | | | ||
| Title: | | |
|
| | | | |
Stockholder
|
| |
Number of
Shares of Hyperfine Series A Preferred Stock |
| |
Number of
Shares of Hyperfine Series B Preferred Stock |
| |
Number of
Shares of Liminal Series A-1 Preferred Stock |
| |
Number of
Shares of Liminal Series A-2 Preferred Stock |
| ||||||||||||
23rd Century Capital LLC
|
| | | | 2,500,000 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | |
Jonathan M. Rothberg Children’s Trust 2012
|
| | | | 22,500,000 | | | | | | 1,403,701 | | | | | | 38,239,355 | | | | | | 172,725 | | |
Michael J. Rothberg Family Trust
|
| | | | 0 | | | | | | 0 | | | | | | 484,042 | | | | | | 2,184 | | |